Insulin-mimetic and Neuroprotective Terpenoids from Gynostemma longipes and Camellia japonica by 하띠김쿠이
 
 
저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 
경 지. 하는  저 물  개 , 형 또는 가공할 수 없습니다. 
약학박사 학위논문
Insulin-mimetic and Neuroprotective 
Terpenoids from Gynostemma longipes and 
Camellia japonica
Gynostemma longipes 와 Camellia 
japonica로부터 인슐린 유사작용과
뇌신경 세포보호 터페노이드 화합물
2019 년 2 월
서울대학교 대학원
약학과 생약학 전공
Ha Thi Kim Quy
i
Insulin-mimetic and Neuroprotective Terpenoids 
from Gynostemma longipes and Camellia japonica
Gynostemma longipes 와 Camellia 
japonica로부터 인슐린 유사작용과 뇌신경 세포보호
터페노이드 화합물
지도교수 오 원 근
이 논문을 약학박사 학위논문으로 제출함
2019 년 1 월
서울대학교 대학원
약학과 생약학전공
Ha Thi Kim Quy
Ha Thi Kim Quy의 약학박사 학위논문을 인준함
2019 년 1 월
위 원 장                         (인)
부위원장                         (인)
위     원                         (인)
위     원                         (인)
ii
위      원                         (인)
Abstract
Insulin-mimetic and Neuroprotective Terpenoids from 
Gynostemma longipes and Camellia japonica
Part 1
Natural products are potential sources in the development of new classes for 
diabetes therapy. In the project of searching for antidiabetic substances from 
medicinal plants, a 95% ethanol fraction of Gynostemma longipes, an 
ethnomedicinal plant used to treat type 2 diabetes mellitus by local communities in 
Vietnam, was found to significantly increase glucose uptake using in vitro 2-
NBDG assay. Gynostemma longipes (Cucurbitaceae family) was cultivated and 
collected in an herbal farm in the Ha Giang province of Vietnam. Recently, there 
are few studies on its chemical constituents and bioactivities. The 
chemical components of G. longipes are similar to species of Gynostemma genus 
which contain triterpenoids as major components. Therefore, the purpose of this 
research was performed the bioassay-guided fractionation and isolation of G. 
longipes. During this process, the purification of ten new triterpenes (1-10) were 
isolated, including three 3,4-seco dammarane (1-3), two hexanordammarane 
glycosides (4 and 5) and five other dammarane glycosides (6-10). All compounds 
were determined by the basis of spectroscopic analyses, including UV, IR, NMR, 
and MS/MS spectra. Isolated compounds (1-10) were then evaluated for their 
effect on glucose uptake in differentiated 3T3-L1 adipocyte cells using 2-NBDG,
iii
as a fluorescent-tagged glucose probe. Among them, compounds 1, 2, 4, and 8
showed particularly potent stimulatory effects through GLUT4 translocation. To 
investigate the underlying mechanism for the stimulation of 2-NBDG uptake into 
the cells by dammarane triterpenes from G. longipes, all isolates (1-10) were 
evaluated the stimulation effect on the AMPK pathway, which plays important role 
in glucose uptake regulation. It may be observed that compounds 1, 2, 4, 8, and 10 
significantly up-regulated the expressions of phosphorylated AMPK and ACC in 
the mouse C2C12 myotubes. These results are consistent with 




Camellia japonica (Theaceae family) is an evergreen tree which widely 
cultivated in Korea, China, and Japan. Since the ancient times, the flower buds of 
C. japonica has been used for treating vomiting of blood and bleeding, tonic, anti-
inflammatory. During in vitro screening of medicinal plants for neuroprotective 
effects on rotenone model of Parkinson’s disease (PD), a 70% ethanol extract 
from the flowers of C. japonica was found as a potential hit. Accordingly, the 
goal of this study was successfully isolation of six new 3,4-seco-28-nor-oleanane 
triterpenoids (11-16) which based on bioassay-guided fractionation of this active 
extract. The molecular structures of these new triterpenoids were elucidated 
through extensive spectroscopic analyses, including UV, IR, high-resolution MS, 
NMR, and by spectral comparison with the published literature. Neuroprotective 
effect of isolated compounds was evaluated, and as a result, compounds 13-16
effectively protected against neurotoxicity in the human dopaminergic SH-SY5Y 
cell line. Among them, compound 15 was found to exhibit the strongest 
neuroprotective effect by suppressing of α-synuclein expression and the 
intracellular production of reactive oxygen species (ROS) induced by rotenone 
treatment. Furthermore, this compound induced microtubule-associated protein 
1A/1B-light chain 3 (LC3), a commonly used autophagy marker, and also 
reduced the condensation of chromosome induced by rotenone treatment. In 
conclusion, it was demonstrated that a new class of chemical entities for 
developing bioactive compounds for PD therapy.
Keywords: Gynostemma longipes, antidiabetic drugs, triterpenes, Camellia 






List of Abbreviations ......................................................................................... ix
List of Tables........................................................................................................i
List of Schemes.....................................................................................................i
Part 1. Triterpenoid Constituents of Gynostemma longipes and Their Insulin 
Mimetic Activity........................................................................................ 1
1. Introduction................................................................................................... 2
1.1. Diabetes disease ..................................................................................... 2
1.2. AMPK signaling pathway....................................................................... 6
1.3. Gynostemma longipes........................................................................... 11
1.4. Purpose of research............................................................................... 12
2. Materials and methods................................................................................. 13
2.1. Plant materials ...................................................................................... 13
2.2. Chemicals, reagents and chromatography ............................................. 14
2.3. Extraction and isolation schemes .......................................................... 16
2.4. Chemical and spectral properties of isolated compounds ....................... 19
2.5. Differentiation of 3T3-L1 adipocytes .................................................... 27
2.6. Measurement of cell viability................................................................ 27
2.7. Measurement of 2-NBDG uptake.......................................................... 28
2.8. Measurement of GLUT4 translocation .................................................. 29
vii
2.9. Measurement of p-AMPK and p-ACC in C2C12 myotubes................... 30
2.10. Statistical analysis .............................................................................. 30
3. Results and discussion................................................................................. 32
3.1. Structural elucidation of isolated compounds (1-10)............................. 32
3.2. Insulin mimetic activity of triterpenoids from G. longipes ..................... 84
4. Conclusions............................................................................................... 102
Part 2. Neuroprotective Effects of Triterpenes from Camellia japonica in a 
Rotenone Model of Parkinson’s Disease............................................... 104
1. Introduction............................................................................................... 105
1.1. Parkinson’s disease............................................................................. 105
1.2. Rotenone-induced Parkinson’s disease model ..................................... 106
1.3. Structure and aggregation of α-synuclein in PD .................................. 108
1.4. The role of light chain 3 (LC3) in autophagy....................................... 110
1.5. Camellia japonica .............................................................................. 112
1.6. Purpose of research............................................................................. 114
2. Materials and methods............................................................................... 115
2.1. Plant materials .................................................................................... 115
2.2. Chemicals, reagents and chromatography ........................................... 115
2.3. Extraction and isolation schemes ........................................................ 115
2.4. Chemical and spectral properties of isolated compounds ..................... 118
2.5. Cytotoxicity assay .............................................................................. 122
viii
2.6. Quantitative real-time PCR................................................................. 123
2.7. Western blot analysis.......................................................................... 124
2.8. Measurement of intracellular ROS levels ............................................ 124
2.9. Confocal immunostaining ................................................................... 125
2.10. Statistical analysis ............................................................................ 125
3. Results and discussion............................................................................... 126
3.1. Structural elucidation of isolated compounds (11-16)......................... 126
3.2. Neuroprotective effect of compounds 11−16 on rotenone-induced 
neurotoxicity of SH-SY5Y cells ................................................................ 146
3.3. Effects of compounds 15 on α-synuclein expression induced by rotenone 
treatment ................................................................................................... 148
3.4. Effects of compound 15 on intracellular ROS production in a rotenone 
treatment model ........................................................................................ 153









  : Specific rotation at 25 Celsius degrees
AMPK: AMP-activated protein kinase








dd: double of doublet
DM: Diabetes mellitus






FBS: Fetal bovine serum
GLP: Gynostemma longipes precipitated
GLS: Gynostemma longipes soluble
GLUT4: Glucose transporter 4 
HMBC: Heteronuclear Multiple Bond Correlation
HPLC: High Performance Liquid Chromatography
HRESIMS: High-resolution electrospray ionization mass spectrometry
HSQC: Heteronuclear Single Quantum Coherence
Hx: Hexane
Hz: Hertz
IHD: Indices of hydrogen deficiency
IR: Infrared (spectrum)
KBNMB: Korea Bioactive Natural Material Bank





m/z: Mass to charge ratio
NaF: Sodium fluoride
NMR: Nuclear magnetic resonance
NOESY: Rotating frame nuclear Overhauser Effect Spectroscopy
NP: Normal-phase (silica gel)
PBS: Phosphate buffered saline
PD: Parkinson's disease 
PI3K: Phosphatidylinositol 3-kinase
PVDF: Polyvinylidene fluoride
ROS: Reactive oxygen species
RP-C18: C18-reversed phase silica gel
s: singlet
t: triplet
T1DM: Type 1 diabetes mellitus
T2DM: Type 2 diabetes mellitus
TLC: Thin-layer chromatography
tR: Retention time




Figure 1. The global epidemic of diabetes from 2010 to 2030................................ 2
Figure 2. The therapeutic targets in type 2 diabetes mellitus organized per tissue. .. 5
Figure 3. Functional domains of three AMPK subunits.......................................... 7
Figure 4. Role of AMPK in regulation of energy homeostasis in whole-body. ....... 9
Figure 5. Authentication of G. longipes based on morphology............................. 12
Figure 6. 1H and 13C NMR of compound 1 (pyridine-d5, 500 MHz/125 MHz)...... 34
Figure 7. HSQC (H→C) of compound 1 (pyridine-d5, 500 MHz)......................... 35
Figure 8. HMBC (H→C) of compound 1 (pyridine-d5, 500 MHz)........................ 36
Figure 9. COSY (H↔H) of compound 1 (pyridine-d5, 500 MHz). ....................... 37
Figure 10. NOESY (H↔H) of compound 1 (pyridine-d5, 500 MHz). ................... 38
Figure 11. 1H and 13C NMR of compound 2 (pyridine-d5, 500 MHz/125 MHz).... 40
Figure 12. HSQC (H→C) of compound 2 (pyridine-d5, 500 MHz)....................... 41
Figure 13. HMBC (H→C) of compound 2 (pyridine-d5, 500 MHz)...................... 42
Figure 14. COSY (H↔H) of compound 2 (pyridine-d5, 600 MHz). ..................... 43
Figure 15. NOESY (H↔H) of compound 2 (pyridine-d5, 600 MHz). ................... 44
Figure 16. 1H and 13C NMR of compound 3 (pyridine-d5, 500 MHz/125 MHz).... 46
Figure 17. HMBC (H→C) of compound 3 (pyridine-d5, 500 MHz)...................... 47
Figure 18. HSQC (H→C) of compound 3 (pyridine-d5, 500 MHz)....................... 48
xiv
Figure 19. 1H and 13C NMR of compound 4 (pyridine-d5, 600 MHz/150 MHz).... 51
Figure 20. HMBC (H→C) of compound 4 (pyridine-d5, 500 MHz)...................... 52
Figure 21. HSQC (H→C) of compound 4 (pyridine-d5, 600 MHz)....................... 53
Figure 22. 1H and 13C NMR of compound 5 (pyridine-d5, 600 MHz/150 MHz).... 55
Figure 23. HMBC (H→C) of compound 5 (pyridine-d5, 500 MHz)...................... 56
Figure 24. HSQC (H→C) of compound 5 (pyridine-d5, 600 MHz)....................... 57
Figure 25. 1H and 13C NMR of compound 6 (pyridine-d5, 600 MHz/150 MHz).... 59
Figure 26. HMBC (H→C) of compound 6 (pyridine-d5, 600 MHz)...................... 60
Figure 27. HSQC (H→C) of compound 6 (pyridine-d5, 600 MHz)....................... 61
Figure 28. 1H and 13C NMR of compound 7 (pyridine-d5, 600 MHz/150 MHz).... 63
Figure 29. HMBC (H→C) of compound 7 (pyridine-d5, 600 MHz)...................... 64
Figure 30. HSQC (H→C) of compound 7 (pyridine-d5, 600 MHz)....................... 65
Figure 31. 1H and 13C NMR of compound 8 (pyridine-d5, 800 MHz/200 MHz).... 67
Figure 32. HMBC (H→C) of compound 8 (pyridine-d5, 800 MHz)...................... 68
Figure 33. HSQC (H→C) of compound 8 (pyridine-d5, 800 MHz)....................... 70
Figure 34. 1H and 13C NMR of compound 9 (pyridine-d5, 500 MHz/125 MHz).... 72
Figure 35. HMBC (H→C) of compound 9 (pyridine-d5, 500 MHz)...................... 73
Figure 36. HSQC (H→C) of compound 9 (pyridine-d5, 500 MHz)....................... 74
xv
Figure 37. 1H and 13C NMR of compound 10 (pyridine-d5, 600 MHz/150 MHz).. 76
Figure 38. HMBC (H→C) of compound 10 (pyridine-d5, 600 MHz).................... 77
Figure 39. HSQC (H→C) of compound 10 (pyridine-d5, 600 MHz)..................... 78
Figure 40. COSY (H↔H) of compound 10 (pyridine-d5, 600 MHz)..................... 79
Figure 41. NOESY (H↔H) of compound 10 (pyridine-d5, 600 MHz). ................. 80
Figure 42. Structures of ten compounds isolated from G. longipes. ...................... 81
Figure 43. Key COSY and HMBC correlations of compounds 1, 2, 4, 7, 8, and 10.
............................................................................................................ 82
Figure 44. Key NOESY correlations of the dammarane skeletons of compounds 1, 
4, 8, and 10. ......................................................................................... 83
Figure 45. The cytotoxicity effect of compounds 1-10 40 μM (A) and compound 
10 at different concentrations (B) in 3T3-L1 adipocytes........................ 85
Figure 46. The cytotoxicity effect of all isolates 1-10 at 40 μM (A) and 10 at 
various concentrations (B) on C2C12 myoblasts................................... 86
Figure 47. Stimulation effect of isolates from G. longipes on 2-NBDG uptake in 
3T3-L1 adipocytes. .............................................................................. 88
Figure 48. Enhancement of glucose uptake by compounds 1-10 in 3T3-L1 
adipocytes using a fluorescent analogue of glucose (2-NBDG). ............ 89
Figure 49. Concentration-response relationships of the effects of several 
compounds on 2-NBDG in 3T3-L1 adipocytes. .................................... 90
Figure 50. Effect of strong candidates (1, 2, 4, and 8) on the translocation of 
GLUT4 into the plasma membrane of adipocytes.................................. 92
xvi
Figure 51. Isolated compounds from G. longipes induced the translocation of 
GLUT4 to the plasma membrane of 3T3-L1 adipocytes; original 
uncropped blots. ................................................................................... 93
Figure 52. Effect of isolated compounds 1-10 on p-AMPK (Thr172) and p-ACC 
(Ser79) in differentiated mouse C2C12 skeletal myoblasts. .................... 96
Figure 53. The effect of compounds 1-10 on p-AMPK Thr172 and p-ACC Ser79 in 
mouse C2C12 myotubes; original uncropped blots. .............................. 97
Figure 54. The effect of compounds 1, 2, 4, and 8 at different concentrations (5 and 
10 μM) on the phosphorylation of AMPK (Thr172) and ACC (Ser79) in 
differentiated mouse C2C12 skeletal myoblasts. ................................... 99
Figure 55. Activation effects of compounds 1, 2, 4, and 8 from G. longipes on the 
phosphorylation of AMPK Thr172 and ACC Ser79 in C2C12 myotubes; 
original uncropped blots. .................................................................... 100
Figure 56. The etiology of Parkinson's disease................................................... 107
Figure 57. Mechanism of rotenone induced apoptosis........................................ 108
Figure 58. Schematic diagram illustrating the steps of autophagy ...................... 111
Figure 59. Camellia japonica Linnaeus var. japonica. ....................................... 113
Figure 60. 1H and 13C NMR of compound 11 (pyridine-d5, 500 MHz/125 MHz).
.......................................................................................................... 128
Figure 61. HMBC of compound 11 (pyridine-d5, 500 MHz). ............................. 129
Figure 62. Key HMBC (H→C) and ROESY correlations for compounds 11, 14, 
and 16. ............................................................................................... 130
Figure 63. 1H and 13C NMR of compound 12 (methanol-d4, 500 MHz/125 MHz).
.......................................................................................................... 132
xvii
Figure 64. HMBC of compound 12 (methanol-d4, 500 MHz)............................. 133
Figure 65. 1H and 13C NMR of compound 13 (methanol-d4, 600 MHz/150 MHz).
.......................................................................................................... 135
Figure 66. HMBC of compound 13 (methanol-d4, 600 MHz)............................. 136
Figure 67. 1H and 13C NMR of compound 14 (acetone-d6, 500 MHz/125 MHz). 138
Figure 68. HMBC of compound 14 (acetone-d6, 500 MHz). .............................. 139
Figure 69. 1H and 13C NMR of compound 15. ................................................... 141
Figure 70. HMBC of compound 15 (methanol-d4, 600 MHz)............................. 142
Figure 71. 1H and 13C NMR of compound 16 (acetone-d6, 500 MHz/125 MHz). 144
Figure 72. HMBC of compound 16 (acetone-d6, 500 MHz). .............................. 145
Figure 73. Six 3,4-seco-28-nor-oleanane triterpenoids (11-16) from C. japonica.
.......................................................................................................... 146
Figure 74. Effects of compounds 11-16 on rotenone-induced cytotoxicity in SH-
SY5Y cells.. ....................................................................................... 147
Figure 75. Relative mRNA and protein expression levels of α-synuclein against 
SH-SY5Y cells................................................................................... 149
Figure 76. Effects of compound 13 and 15 on the protein expressions of α-
synuclein; original uncropped blots. ................................................... 151
Figure 77. Inhibition of intracellular ROS production by compound 15. SH-SY5Y 
cells were pre-treated with or without compound 15 for 24 h.. ............ 153
Figure 78. Compound 15 reduced the condensation of chromosome induced by 
rotenone treatment in HEK293 cells stably expressing GFP-LC3 
measured by the immunocytochemistry method.................................. 155
xviii
Figure 79. Compound 15 (20 μM) reduced the condensation of chromosome 
induced by rotenone treatment in HEK293 cells. ................................ 156
i
List of Tables
Table 1. Staging of type 1 diabetes. ....................................................................... 3
Table 2. AMPK activators from natural products................................................. 10
Table 3. 1H NMR spectroscopic data for compounds 1-10. ................................. 22
Table 4. 13C NMR spectroscopic data for compounds 1-10. ................................ 25
Table 5. The functions of α-synuclein ............................................................... 109
Table 6. NMR spectroscopic data for compounds 11-13. .................................. 120
Table 7. NMR spectroscopic data for compounds 14-16. .................................. 121
i
List of Schemes
Scheme 1. The bio-guided isolation strategy of G. longipes plant. ....................... 13
Scheme 2. Extraction and fractionation of G. longipes......................................... 17
Scheme 3. Isolation scheme of 95% EtOH fraction of G. longipes. ...................... 19
Scheme 4. The bio-guided isolation strategy of C. japonica flowers. ................. 114
Scheme 5. Extraction and fractionation of C. japonica. ..................................... 116
Scheme 6. Isolation scheme of n-BuOH fraction of C. japonica. ....................... 117
1
Part 1. Triterpenoid Constituents of Gynostemma 





Diabetes mellitus (DM) is one of the most serious metabolic diseases and rapidly 
increases in the population aging (Zimmet et al., 2001). During the past three 
decades, the number of patients across the world rise more than doubled. In 2010, 
it is estimated that more than 285 million people worldwide suffered from diabetes 
in the 20-79 year age group and 90% of whom have type 2 diabetes mellitus (Chen 
et al., 2012; Danaei et al., 2011). In particular, it also projected that around 439
million people could be afflicted with diabetes in 2030 (Figure 1) (Chen et al., 
2012). Therefore, future research for the treatment of type 2 diabetes mellitus is 
necessary to develop the program of health promotion and disease prevention in the 
community.
        
Figure 1. The global epidemic of diabetes from 2010 to 2030 (Chen et al., 2012).
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1.1.2. Classification of diabetes
Recently, diabetes is classified into three main types: type 1 diabetes (also called as 
insulin-dependent diabetes), type 2 diabetes (known as non-insulin-dependent 
diabetes), and gestational diabetes (ADA, 2017; Bellamy et al., 2009). In addition,
there have other specific types of diabetes which could be known as monogenic 
diabetes syndromes including neonatal diabetes, maturity-onset diabetes of the 
young, diseases of the exocrine pancreas, and drug- or chemical-induced diabetes
(ADA, 2017).
Firstly, type 1 diabetes mellitus (T1DM), also known as juvenile-onset diabetes,
results from the destruction of autoimmune β-cells in the pancreas. Eventually, 
the pancreas no longer secretes enough insulin and then glucose level in 
the bloodstream significantly increases. Therefore, many organ systems of the body 
could be damaged during three stages of disease (Table 1). Nowadays, several 
studies demonstrated that T1D presents not only in children with typical symptoms 
of polyuria/polydipsia and diabetic ketoacidosis but also in adults with classic 
symptoms similar to children. Even though the methods for distinguishing the type 
of diabetes still complicated, recent advances in diagnosis are developed over time
(ADA, 2017).
Table 1. Staging of type 1 diabetes (ADA, 2017).
Stage 1 Stage 2 Stage 3
Autoimmunity  Autoimmunity    New-onset hyperglycemia  
4
Symptom Normoglycemia Dysglycemia Symptomatic
Presymptomatic Presymptomatic
Secondly, type 2 diabetes mellitus (T2DM), also called adult-onset diabetes, which 
is the most common form of the disease. At diagnosis, T2DM affects around 90% 
of all patients with diabetes. This disease is caused by both genetic and lifestyle 
factors. However, the lifestyle factors such as inactivity, excess weight gain, sleep 
deprivation, dietary fat, and carbohydrates play an important role in the 
development of T2D with some symptoms (insulin resistance, hypertension, 
hyperglycaemia, and dyslipidaemia) (Ardisson Korat et al., 2014; Marín-Peñalver 
et al., 2016). Recently, several novel medications are in development based on 
different tissues (Figure 2) (DeFronzo et al., 2015). Therefore, the clinical 
treatment approach for T2D includes some methods: 
- Lifestyle changes.
- Oral agents: (1) metformin - activation of AMP-activated protein kinase 
(AMPK) pathway; (2) insulin secretagogues (sulfonylureas and 
meglitinides) - increasing insulin secretion; (3) α-glucosidase inhibitors -
reducing postprandial triglycerides; (4) thiazolidinediones - increasing
insulin sensitivity; (5) dipeptidyl peptidase-4 inhibitors - enhancing islet 
function and glycaemic control; (6) sodium glucose co-transporter-2 
inhibitor - reducing the reabsorption of glucose.
- Injectable agents: exenatide, lixisenatide, liraglutide, albiglutide, 
dulaglutide.
5
Especially, older people with diabetes have a risk of death by hypoglycaemia than 
other age groups. Therefore, the treatment for elderly patients is similar to that of
younger patients, but preventing the side effects is an important part of 
diabetic treatment, ensuring a better quality of life, and reducing the risk of falls
(Marín-Peñalver et al., 2016).
Figure 2. The therapeutic targets in type 2 diabetes mellitus organized per tissue 
(DeFronzo et al,. 2015).
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Finally, gestational diabetes only occurs during pregnancy. Glucose homeostasis of 
women could be restored to non-pregnancy levels after delivery. However, patients 
with gestational diabetes can develop to T2DM if the self-care and overall diet are 
not considered (Bellamy et al., 2009).  
1.2. AMPK signaling pathway
1.2.1. AMPK protein
AMPK is one of the central regulators of cellular and it plays a critical role in the 
balance of systemic energy (Mihaylova and Shaw, 2012). In eukaryotes, AMPK 
protein contains a catalytic α-subunit (α1 and α2) and two regulatory b- and g-
subunits (b1, b2 and g1, g2, g3) (Figure 3) (Hardie et al., 2012a; Kim et al., 2016; 
Ruderman et al., 2013). AMPK regulates multiple metabolic pathways in whole-
body (including skeletal muscle, heart, liver, adipose cells, pancreatic b cells, the 
brain) that can control the uptake/storage/utilization of glucose and lipid (Figure 4)
(Kahn et al., 2005). Many studies demonstrated that AMPK pathway plays a
potential role in the treatment of T2D and metformin widely used for activation of
AMPK in clinical therapy (Hardie et al., 2012b). Thus, it is necessary to search 
new anti-diabetic drugs through the activation of the AMPK pathway.
7
Figure 3. Functional domains of three AMPK subunits (Kim et al., 2016).
1.2.2. AMPK regulates glucose transporter 4 (GLUT4) translocation
The mechanism for stimulation the glucose uptake in peripheral tissues is 
necessary to decrease the glucose level in the bloodstream for management of 
T2DM (Krook et al., 2004). GLUT4 is a major mediator which is responsible for 
insulin-regulated glucose uptake into muscle and adipose tissue. The decreased 
expression and translocation of GLUT4 is a characteristic of patients with T2DM. 
Therefore, increasing the translocation and expression of GLUT4 is the potential 
approaches for anti-diabetic drug discovery (Huang and Czech, 2007). Both insulin 
receptor signaling and exercise are essential for recruitment of GLUT4 of the cell 
surface of adipocytes and muscles. (Herman and Kahn, 2006; Stanford and 
Goodyear, 2014). Moreover, in the insulin signal transduction pathway, the 
secretion of insulin from the pancreas and it is bound to a plasma-membrane-
localized receptor. This complex activates the downstream signaling pathways, 
8
including (i) phosphatidylinositol 3-kinase (PI3K) - an intracellular signaling 
pathway which regulates the cell survival, proliferation, and differentiation; (ii)
protein kinase B (Akt/PKB) - a regulator of cell survival and apoptosis. The 
activation of Akt/PKB pathway plays an important role for stimulation of glucose 
uptake and the translocation of GLUT4 transporter in 3T3-L1 adipocytes because it 
stimulates the membrane translocation of the glucose transporter, GLUT4, to 
increase glucose uptake in 3T3-L1 adipocytes (Kim and Wands, 2010). In addition, 
the strong link between the physical exercise and caloric restriction have found to 
induce glucose transport through the AMPK signaling pathway.
Therefore, the activation AMPK signaling pathway is successfully used for 
treatment the deficiency of insulin, the disorder of insulin receptor, and metabolic 
syndrome-related diseases (Richter and Ruderman, 2009; Ruderman et al., 2013).
Finally, the stimulation of AMPK rapidly promotes the glucose uptake via the 
translocation of GLUT1 and GLUT4 and enhances the GLUT4 expression
(Newman and Cragg, 2016; O’Neill, 2013).
9
Figure 4. Role of AMPK in regulation of energy homeostasis in whole-body
(Newman and Cragg, 2016).
1.2.3. AMPK activators from natural products
Natural products are rich sources of antidiabetic drugs that play significant roles in 
the development of new antidiabetic agents (Table 2) (Nasir Uddin et al., 2013). 
Especially, triterpene class is known as a potential agent due to the stimulating the 
glucose uptake through enhancing GLUT4 translocation and AMPK activation. 
Among them, platyconic acid, a triterpene glycoside from the roots of Platycodon 
10
grandiflorum, significantly increased the level of glucose uptake in adipocyte cell 
model and enhanced glucose homeostasis in T2D of mice (Kwon et al., 2012).
Several studies indicated that damulins A and B, dammarane triterpenoids, which 
isolated from Gymnostemma pentaphyllum signifincantly enhanced the 2-
deoxyglucose uptake and GLUT4 translocation to the cell membrane of L6 
myotube cells (Nguyen et al., 2011). Recently, around 150 dammarane 
triterpenoids were successfully isolated from the genus Gynostemma. However,
there are just two dammarane compounds were reported from Gynostemma 
pentaphyllum, including 21-norgypenoside A and B (Yang et al., 2013).
Table 2. AMPK activators from natural products (Nasir Uddin et al., 2013).
Compound Plant source Proposed Therapeutic Use
Resveratrol





Treatment of anti-diabetic, anti-








Treating metabolic syndrome 








Treatment the excessive 







Gynostemma longipes, also known as “That diep dom”, is a traditional Vietnamese
herb for treating diabetes, tonic, and health strengthening. Major secondary 
metabolites of this plant contain dammarane-type triterpenoids (Anh et al., 2015; 
Guo et al., 1997) which are similar to other species of Gynostemma genus (Lee et 
12
al., 2015; Nguyen et al., 2011). To the best of our knowledge, there is no evidence 
about the anti-diabetes activity of G. longipes. Therefore, in this study, ten new 
triterpenes (1-10) were isolated using the bioassay-guided fractionation. All
compounds were measured the glucose uptake in 3T3-L1 adipocytes using 2-[N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG) as a 
fluorescent glucose molecule. In addition, all isolates were also evaluated the 
AMPK activation using mouse C2C12 myotubes. 
Figure 5. Authentication of G. longipes based on morphology: (1) whole plant 
with abaxial leaf and (2) adaxial leaf.
1.4. Purpose of research
This study was discovery of new active constituents applying the bio-guided 
strategy.   We have screened thousands of plant extracts for anti-diabetes activity
using in vitro assay. During this process, the faction from G. longipes showed 
potential effects on glucose uptake in 3T3L1 adipocytes. A class of 
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chemotaxonomic marker metabolite of G. longipes, triterpenoid, was selected as a 
target compound because it was most well-known and widely for treatment T2DM.
The schematic representation of bio-guided isolation strategy is shown in Scheme 1.       
Scheme 1. The bio-guided isolation strategy of G. longipes plant.
2. Materials and methods
2.1. Plant materials
Gynostemma longipes was collected in Ha Giang province of Vietnam (GPS 
23°08'34.9"N 105°25'42.6"E) in August 2016 and the authentication of this plant
was carried out by Prof. Tran Van On, Head of Department of Botany, Hanoi 
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University of Pharmacy, Hanoi, Vietnam. The specimen voucher accession number
of this plant was coded as HNIP.18505/16 and it was stored in the Medicinal 
Herbarium of Hanoi University of Pharmacy.
2.2. Chemicals, reagents and chromatography
2.2.1. Chemistry reagents
- Normal-phase silica gel (ZEOprep 60 40-63 µm) and Reversed-phase silica gel 
(Cosmosil 75C18-PREP) were purchased from Merck (Darmstadt, Germany).
- SephadexTM LH-20 (a bead-formed dextran medium for gel filtration) from 
Sigma-Aldrich (St. Louis, MO, USA) was used for column chromatography (CC).
- TLC Silica gel 60 F254 (20 ´ 20 cm plate) and TLC Silica gel 60 RP-18 F254S (20 ´
20 cm plate) from Merck (Darmstadt, Germany).
- Solvents for extraction and isolation were purchased from Dae Jung Pure 
Chemical Engineering Co. Ltd. (Siheung, Korea).
- Solvents (ACN, MeOH) for HPLC chromatography were bought from 
HoneyWell Burdick & Jackson®, USA.
- NMR solvents were purchased from Cambridge Isotope Laboratories, Inc., USA.
2.2.2. Bioassay reagents
- 2-NBDG (Invitrogen, Eugene, OR, USA)
- BCA protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA)
- Chemiluminescence Western blot detection kit (Thermo sci., Rockford, IL, USA)
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- Dexamethasone, 3-isobutyl-1-methyl-xanthine, MTT (Sigma, St. Louis, MO, 
USA)
- DMEM, FBS, Trypsin (Hyclone, Logan, UT, USA)
- Dimethyl sulfoxide (DMSO) (Junsei Chemical Co. Ltd., Tokyo, Japan) 
- GLUT4 antibody (Santa Cruz, CA, USA)
- Insulin (Roche, Mannheim, Germany)
- Na+/K+ ATPase α1 antibody (Cell signaling Technology, Inc., Beverly, MA, USA)
- p-ACC Ser79, ACC, p-AMPKα Thr172, AMPKα antibodies (Cell signaling 
Technology, Inc., Beverly, MA, USA)
- Penicillin (100 U/mL), and streptomycin (100 μg/mL), calf serum, horse serum 
(Gibco, NY, USA)
- Phosphate-buffered saline (PBS) (Takara, Shiga, Japan)
- Polyvinylidene fluoride (PVDF) membranes (PVDF 0.45 µm, Immobilon-P., 
USA)
- Ethylene Diamine Tetra Acetic acid (EDTA) (Sigma-Aldrich Co., St Louis, MO, 
USA).
2.2.3. Experimental instruments
- Clean bench: Class II Biological Safety Cabinet, ESCO®
- CO2 incubator: Forma Series II water jacketed CO2 incubator, THERMO
16
- Evaporator: EYELA KSB-202, Japan
- ESIMS spectrometer: Agilent Technologies 6130 Quadrupole LC/MS 
spectrometer equipped with an Agilent Technologies 1260 Infinity LC system 
(Agilent Technologies, Inc., Santa Clara, CA, USA)
- Fluorescence microplate reader: Spectra Max Gemini XPS, Molecular Devices, 
San Jose, CA, USA
- Fluorescence microscope: Olympus ix70 Fluorescence Microscope, Olympus 
Corporation, Tokyo, Japan
- HPLC system: Gilson 321 pump and Gilson UV/VIS 151 detector, USA.
- LAS 4000 luminescent image analyzer: Fuji Film, Tokyo, Japan
- IR spectrometer: JASCO, FT/IR-4200, USA
- Microscope: Promo vert, China
- NMR spectrometers:
        Bruker 500 MHz spectrometer (Bruker, Billerica, MA USA)
        JNM-ECA 600 MHz spectrometer (JEOL Ltd., Tokyo, Japan)
- Optical rotations: JASCO P-2000 polarimeter (JASCO International Co. Ltd., 
Tokyo, Japan).
2.3. Extraction and isolation schemes
The powdered aerial parts (350.5 g) of G. longipes were extracted with 70% EtOH 
using the ultrasonication method. The crude ethanolic extract (50.5 g) was 
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suspended in water and then absorbed onto Sepabeads SP70 resin. It was first
washed with H2O, and then eluted with 50% EtOH, 95% EtOH, and acetone,
progressively (Scheme 2).
Scheme 2. Extraction and fractionation of G. longipes.
The active fraction, 95% EtOH fraction (35.6 g), was separated using 
centrifugation into two parts, including the precipitated portion named GLP (28.8 g) 
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and the soluble portion named GLS (6.8 g). Then, the GLS part was applied to
reversed-phase silica gel column chromatography using mobile phase MeOH/H2O 
with a step gradient of 50% to 100% to divide into six sub-fractions from GLS-M1 
to GLS-M6. Among them, GLS-M4 fraction was applied to semi-preparative 
HPLC (Optima Pak C18 column) with mobile phase system: CH3CN/H2O (5:5), 
flow rate 2 mL/min, to obtain compound 1 (6.5 mg). Another fraction (GLS-M6)
was first subjected to Sephadex LH-20 column using MeOH solvent and then 
separated again by HPLC (Optima Pak C18 column) with solvent condition as 
follow: CH3CN/H2O (6:4), flow rate 2 mL/min, to yield compounds 2 (22.5 mg) 
and 10 (15.5 mg). The GLP portion was successfully applied to silica gel CC (10 × 
35 cm; 63–200 μm particle size) using different mobile phase systems: (1) n-
hx/EtOAc from 4:1 to 0:1, (2) EtOAc/MeOH from 20:1 to 0:1. Eleven fractions 
(N1-N11) were obtained which based on the thin-layer chromatography (TLC) 
profile. Sub-fraction N11 was subjected to C18-reversed phase silica gel (RP-C18) 
column using CH3CN/H2O (1:1 to 1:0) to give three sub-fractions: GLP.N11-1 to 
GLP.N11-3. From fraction GLS.N11-2, three compounds [6 (5.5 mg), 8 (6.0 mg), 
and 9 (11.2 mg)] were yielded by HPLC (Optima Pak C18 column) with 
CH3CN/H2O (3:10) solvent system. Another fraction (GLP.N11-3) was applied to
semi-preparative HPLC with mobile phase system: CH3CN/H2O (2:5) to give
compound 7 (7.2 mg). Final fraction (GLP.N6) was separated by Sephadex LH-20 
column (MeOH) and then purified again using semi-preparative HPLC [Optima 
Pak C18, CH3CN/H2O (7:20)], to yield three compounds [3 (6.1 mg), 4 (17.0 mg), 
and 5 (12.0 mg)] (Scheme 3).
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Scheme 3. Isolation scheme of 95% EtOH fraction of G. longipes.
2.4. Chemical and spectral properties of isolated compounds
2.4.1. Secolongipengenin S1 (1) 
Compound 1 was obtained as a white amorphous powder; [a]
25
D 13.5 (c 0.2, 
MeOH); UV (MeOH) λmax (log ε) 254 (3.8); IR (KBr) vmax 3402, 2972, 2923, 1711,
1053, 1008  cm–1; 1H and 13C NMR data, Tables 3 and 4; HRESIMS m/z 503.3382 
[M − H]− (calcd for C30H47O6, 503.3378).
2.4.2. Secolongipengenin S2 (2) 
Compound 2 was obtained as a white amorphous powder; [a]
25
D 4.9 (c 0.2, MeOH);
IR (KBr) vmax 3398, 2972, 2361, 1701, 1051, 1013  cm
–1; 1H and 13C NMR data, 
Tables 3 and 4; HRESIMS m/z 521.3496 [M − H]− (calcd for C30H49O7, 521.3484). 
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2.4.3. Secolongipengenin S3 (3)
Compound 3 was obtained as a white amorphous powder; [a]
25
D 5.5 (c 0.2, MeOH);
IR (KBr) vmax 3400, 2970, 2938, 1698, 1617, 1069, 1053, 1008 cm
–1; 1H and 13C 
NMR data, Tables 3 and 4; HRESIMS m/z 405.2647 [M − H]− (calcd for C24H37O5,
405.2646). 
2.4.4. Longipenoside ND1 (4)
Compound 4 was obtained as a white amorphous powder; [a]
25
D 2.7 (c 0.2, MeOH); 
IR (KBr) vmax 3709, 2971, 2870, 1698, 1617, 1069, 1053, 1013 cm
–1; 1H and 13C 
NMR data, Tables 3 and 4; HRESIMS m/z 873.4525 [M + HCOO]− (calcd for 
C43H69O18, 827.4489). 
2.4.5. Longipenoside ND2 (5)
Compound 5 was obtained as a white amorphous powder; [a]
25
D 5.9 (c 0.2, MeOH); 
IR (KBr) vmax 3403, 2935, 1704, 1388, 1134, 1048, 1005 cm
–1; 1H and 13C NMR 
data, Tables 3 and 4; HRESIMS m/z 1019.5104 [M + HCOO]− (calcd for C49H79O22, 
1019.5068). 
2.4.6. Longipenoside GL1 (6) 
Compound 6 was obtained as a white amorphous powder; [a]
25
D -1.5 (c 0.2, MeOH);
IR (KBr) vmax 3401, 2971, 2923, 2371, 2320, 1053, 1008 cm
–1; 1H and 13C NMR 
data, Tables 3 and 4; HRESIMS m/z 1135.5946 [M + HCOO]− (calcd for C55H91O24,
1135.5906). 
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2.4.7. Longipenoside GL2 (7) 
Compound 7 was obtained as a white amorphous powder; [a]
25
D -1.6 (c 0.2, MeOH);
UV (MeOH): λmax (log ε) 280 (3.7), 250 (3.8) nm; IR (KBr) vmax 3400, 2972, 2942, 
2371, 2320, 1053, 1013 cm–1; 1H and 13C NMR data, Tables 3 and 4; HRESIMS 
m/z 1099.5730 [M + HCOO]− (calcd for C55H87O22, 1099.5694).    
2.4.8. Longipenoside GL3 (8) 
Compound 8 was obtained as a white amorphous powder; [a]
25
D -2.5 (c 0.2, MeOH); 
IR (KBr) vmax 3400, 2971, 2921, 2346, 2313, 1053, 1008 cm
–1; 1H and 13C NMR 
data, Tables 3 and 4; HRESIMS m/z 973.5414 [M + HCOO]− (calcd for C49H81O19, 
973.5378). 
2.4.9. Longipenoside GL4 (9) 
Compound 9 was obtained as a white amorphous powder; [a]
25
D -0.5 (c 0.2, MeOH);
IR (KBr) vmax 3400, 2982, 2372, 2320, 1052, 1037 cm
–1; 1H and 13C NMR data, 
Tables 3 and 4; HRESIMS m/z 1119.6008 [M + HCOO]− (calcd for C55H91O23, 
1119.5957). 
2.4.10. Longipenoside GL5 (10) 
Compound 10 was obtained as a white amorphous powder; [a]
25
D -0.8 (c 0.2, 
MeOH); UV (MeOH): λmax (log ε) 225 nm (2.8); IR (KBr) vmax 3390, 2971, 1057, 
1013 cm–1; 1H and 13C NMR data, Tables 3 and 4; HRESIMS 811.4872 [M + 
HCOO]- (calcd for C43H71O14, 811.4849).
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Table 3. 1H NMR spectroscopic data for compound 1-10 (in pyridine-d5).
Position
1 2 3 4 5 6 7 8 9 10
dH (J in Hz)
500 MHz
dH (J in Hz)
500 MHz
dH (J in Hz)
500 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
500 MHz
dH (J in Hz)
500 MHz
dH (J in Hz)
600 MHz
1
3.21, ddd (4.7, 
11.5, 15.5)
1.95, ddd (4.6, 
11.8, 15.5)
3.21, ddd (4.7, 
11.5, 15.5)
1.94, ddd (4.6, 
11.8, 15.5)
3.17, ddd (4.7, 
11.5, 15.5)





















2.51, ddd (4.7, 
11.8, 15.6)

















3.24, overlap 3.29, overlap 3.26, dd (11.7, 
4.1)
3.32, overlap 3.27, dd (11.9, 
4.3)
3.27, dd (11.9, 
4.3)
3.29, overlap












































2.20, dd (13.4, 
3.3)
2.19, dd (13.4, 
3.3)
2.16, dd (14.2, 
3.3)
1.70, m 1.71, overlap 1.66, overlap 1.67, m 1.67, overlap 1.66, overlap 1.66, overlap
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2.60, dd (13.4, 
3.3)
2.39, t (13.4)
2.59, dd (13.4, 
3.3)
2.35, t (13.4)












2.22, dd (13.0, 
4.0)
2.23, overlap (2H) 2.22, overlap 
(2H)
























1 2 3 4 5 6 7 8 9 10
dH (J in Hz)
500 MHz
dH (J in Hz)
500 MHz
dH (J in Hz)
500 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
500 MHz
dH (J in Hz)
500 MHz
























2.79, td (10.2, 5.2) 2.80, td (10.2, 
5.2)
3.38, m 3.35, m 3.30, m 2.74, td (10.1, 
10.0, 5.3)
3.17, ddd (17.0, 
10.6, 6.7)
2.76, m 2.72, m 2.73, td (10.0, 
5.3)
18 1.26, s 1.24, s 1.15, s 1.00, s 1.01, s 1.09, s 1.14, s 1.13, s 1.11, s 1.11, s
19 1.19, s 1.18, s 1.16, s 0.77, s 0.75, s 0.75, s 0.82, s 0.78, s 0.77, s 0.78, s 








6.44, s 2.59, dd (13.8, 
6.5)
2.53, dd (13.8, 
8.6)
2.57, dd (13.8, 
6.5)





6.25, ddd (15.1, 
8.3, 6.5)




24 6.31, br s 3.00, br s 2.94,  br s 6.16, s 5.99, d (15.1) 5.97, d (15.1) 5.27, m
26 1.72, s 1.50, s 1.44, s 1.70, s 1.52, s 1.51, s 1.66, s
27 2.18, s 1.50, s 1.45, s 2.22, s 1.52, s 1.51, s 1.62, s
28 1.46, s 1.46, s 1.45, s 1.07, s 1.09, s 1.18, s 1.24, s 1.19, s 1.21, s 1.23, s
29 1.50, s 1.50, s 1.49, s 1.15, s 1.19, s 1.12, s 1.10, s 1.14, s 1.11, s 1.17, s
30 0.86, s 0.85, s 0.81, s 0.71, s 0.78, s 0.78, s 0.88, s 0.86, s 0.83, s 0.89, s
1ʹ 4.76, d (7.7) 4.73, d (8.0) 4.72, d (7.5) 4.80, d (7.5) 4.83, d (7.5) 4.79, d (7.5) 4.92, d (7.2)
2ʹ 3.97, overlap 3.94, t (8.0) 4.01, overlap 4.02, overlap 4.09, overlap 4.00, overlap 4.28, overlap
3ʹ 4.07, overlap 4.06, t (8.0) 4.11, overlap 4.13, overlap 4.18, overlap 4.12, overlap 4.26, overlap
4ʹ 3.84, overlap 3.80, overlap 3.86, overlap 3.87, overlap 3.89, overlap 3.84, overlap 4.13, t (9.3)
5ʹ
3.84, overlap 3.90, overlap 3.94, overlap 3.95, overlap 4.07, overlap 3.95, overlap 3.95, ddd (9.3, 
5.4, 2.6)
6ʹ 4.59, overlap 4.48, overlap 4.53, overlap 4.53, overlap 4.53, overlap 4.49, overlap 4.57, dd (11.8, 
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Position
1 2 3 4 5 6 7 8 9 10
dH (J in Hz)
500 MHz
dH (J in Hz)
500 MHz
dH (J in Hz)
500 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
600 MHz
dH (J in Hz)
500 MHz
dH (J in Hz)
500 MHz
dH (J in Hz)
600 MHz
4.47, overlap 4.08, overlap 4.13, overlap 4.13, overlap 4.38, overlap 4.14, overlap 2.6)
4.37, dd (11.8, 
5.4)
1ʹʹ 5.88, br s 5.89, br s 5.86, br s 5.96, br s 5.99, br s 6.00, br s 6.56, br s
2ʹʹ
4.68, overlap 4.68, overlap 4.66, overlap 4.68, overlap 4.71, overlap 4.68, overlap 4.84, dd (3.0, 
1.3)
3ʹʹ
4.50, overlap 4.50, overlap 4.45, overlap 4.50, overlap 4.50, overlap 4.49, overlap 4.66, dd (9.4, 
3.0)
4ʹʹ 4.25, overlap 4.29, overlap 4.27, overlap 4.33, overlap 4.30, overlap 4.33, overlap 4.33, t (9.4)
5ʹʹ
4.64, overlap 4.62, overlap 4.60, overlap 4.62, overlap 4.66, overlap 4.62, overlap 4.79, dq (9.4, 
6.2)
6ʹʹ 1.63, d (4.6) 1.63, d (6.3) 1.61, d (6.3) 1.68, d (6.3) 1.68, d (6.3) 1.67, d (6.3) 1.70, d (6.2)
1ʹʹʹ 5.67, br s 5.69, br s 5.65, br s 5.75, br s 5.76, br s 5.74, br s
2ʹʹʹ 4.84, overlap 4.87, overlap 4.86, overlap 4.92, overlap 4.93, overlap 4.92, overlap
3ʹʹʹ 4.51, overlap 4.53, overlap 4.50, d (9.3) 4.52, d (9.3) 4.58, overlap 4.52, d (9.3)
4ʹʹʹ 4.31, overlap 4.28, overlap 4.25, overlap 4.28, overlap 4.32, overlap 4.28, overlap
5ʹʹʹ 4.68, overlap 4.70, overlap 4.67, overlap 4.70, overlap 4.74, overlap 4.70, overlap
6ʹʹʹ 1.60, d (4.6) 1.62, overlap 1.57, d (6.3) 1.64, d (6.3) 1.64, d (6.3) 1.62, d (6.3)
1ʹʹʹʹ 5.39, br s 5.37, br s 5.44, br s 5.43, br s
2ʹʹʹʹ 4.53, overlap 4.50, overlap 4.53, overlap 4.52, overlap
3ʹʹʹʹ 4.62, overlap 4.59, overlap 4.62, overlap 4.63, overlap
4ʹʹʹʹ 4.35, overlap 4.32, overlap 4.35, overlap 4.35, overlap
5ʹʹʹʹ 4.34, overlap 4.31, overlap 4.34, overlap 4.34, overlap
6ʹʹʹʹ 1.64, overlap 1.59, d (6.3) 1.65, d (6.3) 1.64, d (6.3)
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Table 4. 13C NMR spectroscopic data for compounds 1-10 (in pyridine-d5).
Position





















1 35.8, CH2 35.9, CH2 35.7, CH2 39.2, CH2 39.1, CH2 39.3 CH2 39.3, CH2 39.4, CH2 39.3, CH2 39.3, CH2
2 30.0, CH2 30.0, CH2 30.0, CH2 28.1, CH2 28.0, CH2 26.8, CH2 27.0, CH2 27.0, CH2 27.0, CH2 27.1, CH2
3 177.4, C 177.3, C 177.3, C 88.6, CH 88.8, CH 89.2, CH 89.0, CH 88.6, CH 89.1, CH 88.7, CH
4 75.1, C 75.1, C 75.1, C 39.3, C 39.2, C 39.9, C 39.8, C 41.0, C 39.9, C 40.0, C
5 52.6, CH 52.6, CH 52.5, CH 56.5, CH 56.5, CH 56.7, CH 56.6, CH 56.6, CH 56.7, CH 56.7, CH
6 23.2, CH2 23.3, CH2 23.1, CH2 18.7, CH2 18.8, CH2 18.7, CH2 19.0, CH2 18.9, CH2 18.4, CH2 18.8, CH2
7 34.1, CH2 34.1, CH2 34.0, CH2 34.6, CH2 34.6, CH2 34.8, CH2 34.7, CH2 34.9, CH2 34.8, CH2 34.9, CH2
8 40.8, C 40.8, C 40.5, C 40.7, C 40.6, C 41.0, C 41.0, C 41.4, C 41.0, C 41.0, C
9 47.1, CH 47.1, CH 46.1, CH 53.8, CH 53.6, CH 54.7, CH 54.0, CH 54.7, CH 54.7, CH 54.8, CH
10 42.2, C 42.2, C 42.1, C 37.5, C 37.6, C 37.8, C 37.8, C 37.7, C 37.8, C 37.7, C
11 40.0, CH2 40.0, CH2 39.2, CH2 39.8, CH2 39.8, CH 40.2, CH 40.0, CH2 40.2, CH2 40.2, CH2 40.2, CH2
12 211.8, C 211.8, C 209.8, C 210.3, C 209.9, C 212.5, C 210.0, C 212.2, C 212.3, C 212.1, C
13 56.8, CH 57.0, CH 58.5, CH 58.5, CH 58.4, CH 56.8, CH 59.0, CH 56.9, CH 56.8, CH 56.9, CH
14 56.6, C 56.6, C 55.1, C 54.8, C 54.6, C 56.7, C 55.2, C 56.2, C 56.2, C 56.7, C
15 32.3, CH2 32.3, CH2 31.9, CH2 31.8, CH2 31.7, CH2 32.3, CH2 32.1, CH2 32.3, CH2 32.2, CH2 32.3, CH2
16 25.3, CH2 25.3, CH2 26.3, CH2 26.1, CH2 26.0, CH2 25.2, CH2 28.8, CH2 24.8, CH2 24.7, CH2 24.8, CH2
17 45.3, CH 45.4, CH 48.0, CH 47.9, CH 47.9, CH 45.1, CH 45.7, CH 44.4, CH 44.3, CH 44.4, CH
18 15.8, CH3 15.8, CH3 15.7, CH3 15.9, CH3 15.9, CH3 16.1, CH3 16.1, CH3 16.1, CH3 16.1, CH3 16.1, CH3
19 21.2, CH3 21.2, CH3 20.9, CH3 16,2, CH3 16,2, CH3 16.6, CH3 16.4, CH3 16.5, CH3 16.6, CH3 17.2, CH3
20 74.1, C 73.9, C 210.2, C 210.0, C 210.2, C 73.9, C 159.8, C 74.0, C 73.8, C 73.6, C
21 27.1, CH3 26.8, CH3 30.2, CH3 30.2, CH3 30.2, CH3 26.8, CH3 17.7, CH3 27.5, CH3 27.5, CH3 26.9, CH3
22 54.8, CH2 55.1, CH2 55.2, CH2 126.2, CH 45.8, CH2 45.8, CH2 42.3, CH2
23 201.9, C 213.1, C 212.9, C 191.7, C 123.2, CH 123.1, CH 23.9, CH2
24 126.6, CH 57.8, CH2 57.7, CH2 127.4, CH 143.1, CH 143.0, CH 126.2, CH
25 154.9, C 70.0, C 70.1, C 154.0, C 70.1, C 70.1, C 131.2, C
26 27.7, CH3 30.8, CH3 30.7, CH3 27.7, CH3 31.1, CH3 31.0, CH3 26.1, CH3
27 21.0, CH3 30.5, CH3 30.3, CH3 20.8, CH3 31.0, CH3 31.0, CH3 18.0, CH3
28 28.6, CH3 28.6, CH3 28.6, CH3 28.1, CH3 28.0, CH3 28.1, CH3 28.2, CH3 28.1, CH3 28.1, CH3 28.1, CH3
26
Position





















29 34.5, CH3 34.5, CH3 34.5, CH3 16.9, CH3 16.8, CH3 16.8, CH3 16.9, CH3 17.0, CH3 16.6, CH3 16.5, CH3
30 17.3, CH3 17.3, CH3 17.2, CH3 17.4, CH3 17.4, CH3 17.5, CH3 17.7, CH3 17.6, CH3 17.6, CH3 17.6, CH3
1ʹ 105.3, CH 105.2, CH 105.3, CH 105.3, CH 105.4, CH 105.3, CH 105.8, CH
2ʹ 78.3, CH 78.4, CH 78.5, CH 78.5, CH 78.3, CH 78.4, CH 77.6, CH
3ʹ 87.5, CH 87.0, CH 87.1, CH 87.3, CH 87.6, CH 87.2, CH 80.2, CH
4ʹ 70.6, CH 70.5, CH 71.0, CH 70.7, CH 70.7, CH 70.8, CH 72.5, CH
5ʹ 78.3, CH 76.2, CH 76.4, CH 76.4, CH 78.5, CH 76.4, CH 78.6, CH
6ʹ 62.8, CH2 68.1, CH2 68.4, CH2 68.4, CH2 62.9, CH2 68.3, CH2 63.2, CH2
1ʹʹ 102.5, CH 102.4, CH 102.5, CH 102.6, CH 102.6, CH 102.6, CH 102.1, CH
2ʹʹ 72.3, CH 72.1, CH 72.2, CH 72.1, CH 72.4, CH 72.1, CH 72.5 CH
3ʹʹ 72.7, CH 72.1, CH 72.5, CH 72.3, CH 72.8, CH 72.3, CH 72.9, CH
4ʹʹ 74.0, CH 73.7, CH 73.7, CH 73.9, CH 74.1, CH 73.9, CH 74.5, CH
5ʹʹ 70.1, CH 70.0, CH 70.2, CH 70.2, CH 70.2, CH 70.2, CH 69.9, CH
6ʹʹ 18.9, CH3 18.9, CH3 19.0, CH3 19.0, CH3 18.9, CH3 18.9, CH3 19.0, CH3
1ʹʹʹ 104.0, CH 103.8, CH 103.9, CH 104.0, CH 104.1, CH 104.0, CH
2ʹʹʹ 72.7, CH 72.4, CH 72.7, CH 72.8, CH 72.8, CH 72.8, CH
3ʹʹʹ 72.9, CH 72.6, CH 72.8, CH 73.1, CH 73.0, CH 73.0, CH
4ʹʹʹ 73.8, CH 73.8, CH 73.9, CH 74.1, CH 74.0, CH 74.0, CH
5ʹʹʹ 71.0, CH 70.9, CH 70.8, CH 70.7, CH 71.1, CH 70.6, CH
6ʹʹʹ 18.7, CH3 18.8, CH3 18.9, CH3 19.0, CH3 18.8, CH3 19.0, CH3
1ʹʹʹʹ 102.6, CH 102.8, CH 102.8, CH 102.8, CH
2ʹʹʹʹ 72.9, CH 73.0, CH 72.9, CH 73.0, CH
3ʹʹʹʹ 72.6, CH 72.8, CH 72.8, CH 72.9, CH
4ʹʹʹʹ 74.0, CH 74.1, CH 74.2, CH 74.2, CH
5ʹʹʹʹ 70.6, CH 70.8, CH 70.8, CH 70.8, CH
6ʹʹʹʹ 18.6, CH3 18.7, CH3 18.7, CH3 18.7, CH3
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2.5. Differentiation of 3T3-L1 adipocytes 
3T3-L1 myoblasts were maintained at 37°C in an atmosphere of 5% CO2 using
Dulbecco’s modified Eagle’s medium (DMEM) (HyClone, Logan, UT, USA) 
supplemented with 10% calf serum, penicillin (100 U/mL), and streptomycin (100 
μg/mL) (Gibco, Grand Island, NY, USA). The procedure of differentiation was 
carried out following two steps: (1) the cells firstly incubated for 2 days with
medium containing 10% fetal bovine serum (FBS) (HyClone), 1 μM 
dexamethasone (Sigma, MO, USA), 520 μM 3-isobutyl-1-methyl-xanthine (Sigma) 
and 1 μg/mL insulin (Roche, Mannheim, Germany); (2) the cells were continually
incubated with fresh DMEM containing 10% FBS, 1 μg/mL insulin, 100 U/mL 
penicillin and 100 μg/mL streptomycin. The cultures were changed the fresh 
medium every 1.5-2 days until the adipogenesis induction. After 4-6 days of 
incubation, lipid droplets significantly accumulated in the 3T3-L1 adipocytes.  
2.6. Measurement of cell viability
To evaluate the cell viability, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) assay was used as a simple and common method. 
Briefly, the cells (C2C12 myoblasts or 3T3-L1 adipocytes) were seeded into 96-
well plates with DMEM containing 10% FBS. After 24 h of incubation, the cells 
were exposed to test samples which were dissolved in the serum-free medium. The 
cultures were continuously incubated for 24 h at 37°C in an atmosphere of 5% CO2
and then the MTT solution (Sigma) (20 μL of the 2 mg/mL) were added to each 
well. After 4 h of incubation in the dark, the formazan product was dissolved in 
dimethyl sulfoxide (DMSO) and measured at 550 nm using a microplate reader 
(VersaMax, PA, USA).  
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2.7. Measurement of 2-NBDG uptake
The glucose uptake into the cells was evaluated using a fluorescent derivative of 
glucose 2-NBDG (Invitrogen, Eugene, OR, USA), which was commonly used for 
in vitro studies. The glucose uptake assay using the 2-NBDG probe was performed 
as previously described (Pham et al., 2018). Briefly, 3T3-L1 adipocytes were 
seeded into 96-well plates using a glucose-free medium supplemented with 10% 
FBS for 24 h. The cells were then treated with insulin (as a positive control) and 
test samples in the presence or absence of 2-NBDG probe and continuously
incubated for 1 h. After that, the cultures were washed with cold phosphate 
buffered saline (PBS). To measure the fluorescent intensity, a fluorescence 
microplate reader (Spectra Max Gemini XPS, Molecular Devices, San Jose, CA, 
USA) was applied at 450/535 nm excitation/emission wavelengths. Moreover, the 
transport of 2-NBDG into adipocytes was also confirmed using a fluorescence 
microscopy method. Briefly, the cells were grown on sterilized glass coverslips
using the glucose-free medium (10% FBS) for 1 day. The following steps were 
carried out as described above. After that, coverslips were washed with cold PBS 
and fluorescent images were obtained using a fluorescence microscope (Olympus 
ix70 Fluorescence Microscope, Olympus Corporation, Tokyo, Japan).
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2.8. Measurement of GLUT4 translocation 
The translocation of GLUT4 protein to the plasma membrane of adipocytes was 
evaluated using the Western blot method. 3T3-L1 adipocytes were grown on 6-well 
plates with DMEM containing 10% FBS. The cells were then exposed to insulin 
for 2 h and the test samples for 24 h using the serum-free medium. The fractions of
the plasma membrane were isolated as previously described with several
modifications (Yamamoto et al., 2016). The concentrations of protein were 
measured using a BCA protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, 
USA). The equal amount of proteins were loaded on 12% SDS-polyacrylamide 
gels. The gels were then transferred to polyvinylidene fluoride (PVDF) membranes 
(PVDF 0.45 µm, Immobilon-P., USA). After blocking with 5% skim milk solution 
for 1 h, the membranes were incubated overnight with primary antibodies for 
GLUT4 (Santa Cruz, CA, USA), Na+/K+ ATPase α1 (Cell Signaling, Danvers, MA, 
USA). The blots the continuously incubated with secondary antibodies for 2 h and 
the bands were detected using a LAS 4000 luminescent image analyzer (Fuji Film, 
Tokyo, Japan).
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2.9. Measurement of p-AMPK and p-ACC in C2C12 myotubes
For differentiating C2C12 myoblasts to myotubes, the procedure was performed 
using differentiation media [DMEM supplemented with 2% horse serum (Gibco), 
penicillin (100 U/mL), and streptomycin (100 μg/mL)]. The medium was changed 
with fresh differentiation medium until the formation of myotubes. To evaluate the 
expression of p-AMPK and p-ACC proteins, Western blot analysis was used. 
Myotubes were incubated with compounds for 1 h and the cell lysates were then 
collected using a lysis buffer [50 mM Tris-HCl (pH 7.6), 120 mM NaCl, 1 mM 
EDTA, 0.5% NP-40, 50 mM NaF]. The BCA protein assay was used for 
determining the protein concentrations. Proteins were electrophoresed on 8% or 12% 
SDS-polyacrylamide gels and then transferred to PVDF membranes. The blots
were continuously incubated with primary antibodies, including p-ACC Ser79, ACC, 
p-AMPKα Thr172, AMPKα (Cell Signaling) or β-actin (Thermo Fisher Scientific, 
Rockford, IL, USA). After 24 h of incubation, the membranes were then incubated
with secondary antibodies for 2 h. An enhanced chemiluminescence Western blot 
detection kit (Thermo Fisher Scientific) was used for detection of membranes.
2.10. Statistical analysis
Data are presented by the mean ± SD of three independent experiments. For 
quantitative analysis of Western blotting, ImageJ software was applied. The one-
way analysis of variance (ANOVA) was used to determine the 
significant differences between groups following Tukey’s or Duncan’s post 
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hoc test as appropriate, which conducted in SPSS Statistics 23 (SPSS, Inc., 
Chicago, IL, USA). Statistical significance was accepted at * p < 0.05, ** p < 0.01, 
and *** p < 0.001.
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3. Results and discussion
3.1. Structural elucidation of isolated compounds (1-10)
3.1.1. Compound 1
Compound 1 was acquired as an amorphous powder with [a]
25
D 13.5 (c 0.2, MeOH). 
Its molecular formula was obtained as C30H48O6 by HRESIMS with an ion peak at 
m/z 503.3382 [M − H]− (calcd for C30H47O6,  503.3378). The existence of α,β-
unsaturated carbonyl groups were confirmed at 1711 cm–1 in the IR spectrum and 
at 254 nm in the UV absorption. In addition, the presence of hydroxy groups
significantly recorded at 3402 cm–1 and 1053 cm–1. In the 1H NMR spectrum, it 
showed six methyl singlets in the most upfielded resonances at δH 1.52, 1.50, 1.46, 
1.26, 1.19, and 0.86 (each 3H) and other two methyl singlets at δH 2.18, 1.72 were 
connected to an olefin functionality. In the most downfielded resonances, the 
presence of olefinic proton was confirmed at δH 6.31 (1H, br s) (Table 3 and Figure 
6). Besides, the positions of two oxygenated quaternary carbons were determined 
based on the 13C NMR and HSQC spectra at δC 75.1 and 74.1. From the molecular 
formula (C30H47O6) and 
13C NMR spectrum, compound 1 was suggested seven 
indices of hydrogen deficiency (IHD), which included three rings of the modified 
triterpenoid skeleton with an open ring, two sp2 carbons (δC 154.9 and 126.6), one 
carboxylic acid carbon (δC 177.4), and two carbonyl carbons (δC 211.8 and 201.9)
(Table 4 and Figures 6, 7). In the HMBC spectrum, the presences of an oxygenated 
carbon (C-4), C-23 (C=O), and a ∆24,25 olefin system were identified by the HMBC 
cross peaks from H-28 (δH 1.46) and H-29 (δH 1.50) to C-4 (δC 75.1), from H-22 (δH
2.92 and 2.70), H-24 (δH 6.31) to C-23 (δC 201.9) and from H-26 (δH 1.72), H-27 
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(δH 2.18) to C-24 (δC 126.6) and C-25 (δC 154.9) (Figure 8). Its COSY data 
revealed the key correlations between methylene protons H-1 at δH 3.21 [1H, ddd 
(4.7, 11.5, 15.5)] and δH 1.95 [1H, ddd (4.6, 11.8, 15.5)] to the protons H-2 (δH 2.56, 
3.00) (Figure 9). For confirming the carboxylic acid moiety, the HMBC experiment 
was applied to determine the ring cleavage occurred between C-3 and C-4. The 
HMBC spectrum showed the cross-peaks between H-2 and C-3 without any 
correlation from H-28 and H-29 to C-3. The relative configuration of compound 1
was obtained using NOESY experiment. Based on its result, the key correlation 
between H-5 (δH 1.69) and H-19 (δH 1.19) indicated the β orientation of H-5 and H-
19. In addition, protons H-17 (δH 2.79) showed correlations to H-21 (δH 1.52) and 
H-30 (δH 0.86) which were determined as the α orientation (Figure 10). The side 
chain of 1 was elucidated by comparison with the chemical shifts of Gypentonoside 
A (Fang and Zeng, 1996). Besides, the position at C-21 (δC 27.1) is similar to the 
chemical shift of 20(S) dammarane analogues (Lee et al., 2013). Finally, compound 
1 was determined as 4,20(S)-dihydroxy-3,4-seco-dammar-24-en-12,23-dion-3-oic 
acid, which also called as Secolongipegenin S1. Especially, 3,4-seco-dammarane 
triterpenoid is firstly isolated from the genus Gynostemma.
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Figure 6. 1H and 13C NMR of compound 1 (pyridine-d5, 500 MHz/125 MHz).
35
Figure 7. HSQC (H→C) of compound 1 (pyridine-d5, 500 MHz).
36
Figure 8. HMBC (H→C) of compound 1 (pyridine-d5, 500 MHz).
37
Figure 9. COSY (H↔H) of compound 1 (pyridine-d5, 500 MHz).
38
Figure 10. NOESY (H↔H) of compound 1 (pyridine-d5, 500 MHz).
39
3.1.2. Compound 2
Triterpenoid 2 was obtained as an amorphous powder with [a]
25
D 4.9 (c 0.2, MeOH).
Its molecular formula of 2 was identified as C30H50O7 based on an ion peak at m/z
521.3496 [M − H]− HRESIMS (calcd for C30H49O7, 521.3484). The calculation of 
IHD for this compound was recorded as 6 indices. A comparison with the 1H and 
13C NMR spectroscopic data of 1 (Tables 3 and 4), triterpenoid 2 also demonstrated 
similarly chemical shifts. However, the absence of the ∆24,25 olefinic linkage and 
the appearance of one more hydroxy moiety were clearly confirmed by 13C NMR
and HMBC experiment. The presence of C-24 (δC 57.8, -68.8 ppm), C-25 (δC 70.0, 
-84.9 ppm), and C-23 (δC 213.1, +11.2 ppm) compared with these chemical shifts 
of compound 1. In addition, the HMBC cross peaks from Me-26 and Me-27 to C-
25 were also obtained. These results strongly indicated the hydroxy group attached 
at C-25. Hence, compound 2 was assigned as 4,20(S),25-trihydroxy-3,4-seco-
dammaran-12,23-dion-3-oic acid which also named as Secolongipegenin S2
(Figures 11-15).
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Figure 11. 1H and 13C NMR of compound 2 (pyridine-d5, 500 MHz/125 MHz).
41
Figure 12. HSQC (H→C) of compound 2 (pyridine-d5, 500 MHz).
42
Figure 13. HMBC (H→C) of compound 2 (pyridine-d5, 500 MHz).
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Figure 14. COSY (H↔H) of compound 2 (pyridine-d5, 600 MHz).
44
Figure 15. NOESY (H↔H) of compound 2 (pyridine-d5, 600 MHz).
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3.1.3. Compound 3
Secolongipegenin S3 (3) was purified as an amorphous powder with [a]
25
D 5.5 (c
0.2, MeOH). Its molecular formula was identified as C24H38O5 and based on the 
HRESIMS with an ion peak at m/z 405.2647 [M − H]− (calcd for C24H37O5  
405.2646). The IHD of this compound was calculated as six indices. According to 
NMR experiment (Tables 3 and 4), compound 3 clearly demonstrated a similar 
skeleton with 1 in seco rings A and B. In addition, the HMBC spectrum showed the 
cross-peaks between H-17 and Me-21 to C-20. Therefore, compound 3 was 
determined as 4-hydroxy-3,4-seco-22,23,24,25,26,27-hexanordammaran-12,20-
dion-3-oic acid (Figures 16-18).
46
Figure 16. 1H and 13C NMR of compound 3 (pyridine-d5, 500 MHz/125 MHz).
47
Figure 17. HMBC (H→C) of compound 3 (pyridine-d5, 500 MHz).
48
Figure 18. HSQC (H→C) of compound 3 (pyridine-d5, 500 MHz).
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3.1.4. Compound 4
Triterpenoid 4 was isolated as an amorphous powder with [a]
25
D 2.7 (c 0.2, MeOH). 
The HRESIMS presented a pseudomolecular ion peak at m/z 873.4525 [M +
HCOO]− (calcd for C43H69O18, 873.4489), which suggested this compound had the 
molecular formula of C42H68O16 and the presence of nine IHD. The 
1H NMR data 
revealed six methyl singlets (δH 2.23, 1.15, 1.07, 1.00, 0.77, and 0.71) (each 3H, s) 
(Figure 19). The presence of two carbonyl groups (δC 210.3 and 210.0), three 
anomeric carbons (δC 105.3, 104.0, 102.5), and 17 oxygenated carbons (δC 62.8 to 
88.6) were indicated by the 13C NMR data (Figure 19). Based on the comparison of 
the NMR data between compound 4 with 3β-hydroxy-hexanordammaran-20-one
(Tu et al., 2008), the structures of two compounds were similar. However, 
compound 4 was substituted with one carbonyl group and possessed one more 
sugar. In the HMBC spectrum, the presences of carbonyl groups C-12 and C-20 
were determined by the HMBC cross peaks from H-11 (δH 2.23 and 2.15) and H-13 
(δH 3.21) to C-12 (δC 210.3), from H-17 (δH 3.35) and H-21 (δH 2.22) to C-20 (δC 
210.0) (Figure 20). The relative configuration of compound 4 was identified using 
NOESY experiment. The key correlations of H-3 (δH 3.24) and H-5 (δH 0.69)
indicated an α orientation for H-3 (Figure 44). Hence, the aglycone of 4 revealed
unequivocally as 3β-hydroxy-22,23,24,25,26,27-hexanordammarane-12,20-dione.
In the sugar moieties of compound 4, all NMR data demonstrated the appearance 
of three sugars units, including a β-glucopyranosyl unit [δH 4.76, d (7.7); δC 105.3] 
and two α-rhamnopyranosyl units [(δH 5.88, br s; δC 102.5) and (δH 5.67, br s; δC
104.0)] (Figure 21). In addition, compound 4 also successfully hydrolyzed with 
HCl to obtain D-glucose and L-rhamnopyranose. After reaction with L-cysteine 
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methyl ester hydrochloride and TMS derivatization, the mixtures were measured 
using gas chromatographic analysis. Result of the positive mode in HPLC-MS
indicated fragment ions at 829 [M + H]+, 683 [M + H – rha (146)]+, 536 [M + H –
rha – rha (146)]+, and 375 [M + H − H2O – 2 × rha – glc (162)]
+ , which suggested 
the existence of two rhamnose and one glucose moieties. The positions of three 
sugars were also identified based on a HMBC experiment (Figure 20). This data 
was demonstrated the presence of key HMBC correlations between H-1' (δH 4.76) 
and C-3 (δC 88.6), H-1'' (δH 5.88) and C-2' (δC 78.3), H-1''' (δH 5.67) and C-3' (δC
87.5). Therefore, compound 4 was determined as 3β-hydroxy-22,23,24,25,26,27-
hexanordammaran-12,20-dione-3-O-α-L-rhamnopyranosyl-(1→2)-[α-L-
rhamnopyranosyl-(1→3)]-β-D-glucopyranoside which also called as Longipenoside 
ND1.
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Figure 19. 1H and 13C NMR of compound 4 (pyridine-d5, 600 MHz/150 MHz).
52
Figure 20. HMBC (H→C) of compound 4 (pyridine-d5, 500 MHz).
53
Figure 21. HSQC (H→C) of compound 4 (pyridine-d5, 600 MHz).
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3.1.5. Compound 5
Longipenoside ND2 (5) was isolated as an amorphous powder with [a]
25
D 5.9 (c 0.2, 
MeOH). The HRESIMS of this compound revealed an ion peak at m/z 1019.5104 
[M + HCOO]− (calcd for C49H79O22, 1019.5068). It suggested a molecular formula 
C48H78O20 and indicated the presence of ten IHD. All NMR data of compound 5
showed similarly the chemical shifts with compound 4. The difference was 
appearance of a rhamnose glycosyl unit at C-6', which was identified by a 
downfield chemical shift of C-6' (δC 68.1, +5.3 ppm) and the strong HMBC 
correlation from H-1'''' (δH 5.39, br s) to C-6'. In addition, compound 5 was reacted 
with acid HCl, L-cysteine methyl ester hydrochloride and TMS derivatization, 
progressively. The products of D-glucose and L-rhamnose were analyzed using gas 
chromatography method. The positive mode of HPLC-MS experiment clearly 
showed the existence of one glucose and three rhamnose units based on fragment 
ions at m/z 975 [M + H]+, 829 [M + H – rha (146)]+, 682 [M + H – rha – rha 
(146)]+, 535 [M + H − H2O – 2 × rha – rha (146)]
+ and 375 [M + H − H2O – 3 × 





Figure 22. 1H and 13C NMR of compound 5 (pyridine-d5, 600 MHz/150 MHz).
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Figure 23. HMBC (H→C) of compound 5 (pyridine-d5, 500 MHz).
57
Figure 24. HSQC (H→C) of compound 5 (pyridine-d5, 600 MHz).
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3.1.6. Compound 6
Compound 6 was purified as an amorphous powder with [a]
25
D -1.5 (c 0.2, MeOH). 
Its molecular formula was identified as C54H90O22 based on the negative ion peak at 
m/z 1135.5946 [M + HCOO]− (calcd for C55H91O24, 1135.5906). According to the 
HPLC-MS experiment, the positive mode of 6 suggested the appearance of a 
glycoside chain similar to compound 5 and the aglycone was substituted by two 
hydroxy groups. The 1H and 13C NMR spectroscopic data of 6 (Tables 3 and 4)
showed the same skeleton with 5, excepted of the side chain at C-17 which had the 
similar resonances to those of 1. The disappearance of olefinic linkage at Δ24,25 and 
the attachment of a hydroxyl group at C-25 were confirmed by 13C NMR spectrum 
via C-24 (δC 57.7, -68.9 ppm), C-25 (δC 70.1, -84.8 ppm), and C-23 (δC 212.9, 
+11.0 ppm) compared to 1. In the HMBC experiment, the key correlations were 
established from Me-26 (δH 1.44, s) and Me-27 (δH 1.45, s) to C-25 (δC 70.1). 
Hence, compound 6 was elucidated as 3β,20(S),25-trihydroxydammaran-12,23-
dione-3-O-α-L-rhamnopyranosyl-(1→2)-[α-L-rhamnopyranosyl-(1→3)]-[α-L-
rhamnopyranosyl-(1→6)]-β-D-glucopyranoside which also named as 
Longipenoside GL1 (Figures 25-27).
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Figure 25. 1H and 13C NMR of compound 6 (pyridine-d5, 600 MHz/150 MHz).
60
Figure 26. HMBC (H→C) of compound 6 (pyridine-d5, 600 MHz).
61
Figure 27. HSQC (H→C) of compound 6 (pyridine-d5, 600 MHz).
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3.1.7. Compound 7
Longipenoside GL2 (7), isolated as an amorphous powder with [a]
25
D -1.6 (c 0.2, 
MeOH), showed a molecular formula of C54H86O20 based on an ion peak at m/z
1099.5730 [M + HCOO]− (calcd for C55H87O22, 1099.5694). The positive-ion mode
in HPLC-MS spectrum indicated the presence of a glycoside chain which is similar 
to that of compound 5. The 1H and 13C NMR data of 7 (Tables 3 and 4) revealed 
the similar connectivity as 6, except for the disappearance of two hydroxy group 
signals (C-20 and C-25) and the replacement by two olefinic linkages (Δ20,22 and 
Δ24,25). The dehydration of 7 at C-20 and C-25 was identified when compared with 
6 using 13C NMR data: C-21 (δC 17.7, -9.1 ppm), C-20 (δC 159.8, +85.9 ppm), C-22 
(δC 126.2, +71.0 ppm), C-24 (δC 127.4, +72.3 ppm), and C-25 (δC 154.0, +83.9 
ppm). In addition, the olefinic moieties were also confirmed from HMBC 
correlation between H-21 and H-17 to C-20, C-22, and H-26, H-27 to C-24, C-25, 




Figure 28. 1H and 13C NMR of compound 7 (pyridine-d5, 600 MHz/150 MHz).
64
Figure 29. HMBC (H→C) of compound 7 (pyridine-d5, 600 MHz).
65
Figure 30. HSQC (H→C) of compound 7 (pyridine-d5, 600 MHz).
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3.1.8. Compound 8
Compound 8 was isolated as an amorphous powder with [a]
25
D -2.5 (c 0.2, MeOH). 
Its molecular formula was assigned as C48H80O17 based on a negative ion peak [M 
+ HCOO]− at m/z 973.5414 (calcd for C49H81O19, 973.5378). Analysis and 
comparison of the NMR spectra between compounds 4 and 8, results demonstrated 
that the glycoside chain and the main dammarane skeleton of two compounds were 
similar. However, differences of these compounds appeared at the side chain. 
Compound 8 contained two oxygen-bearing carbons at C-20 and C-25 (δC 74.0 and 
70.1), two olefinic methine signals at C-23 and C-24 (δC 123.2 and 143.1). These 
result indicated its side chain was similar to the structure of notoginsenoside ST-5
(Liao et al., 2008). According to HMBC experiment, the positions of the side chain 
were confirmed by correlations from H-21 to C-17, C-20 and C-22; from H-23, H-
24 to C-22, C-25; from H-26, H27 to C-23, C-24, and C-25. The large coupling 
constant (J = 15.1 Hz) between H-23 and H-24 provided the evidence that the E 
geometry of the ∆23,24 olefinic bond. Therefore, compound 8 was elucidated as 
3β,20(S),25-trihydroxydammar-23(E)-en-12-one-3-O-α-L-rhamnopyranosyl-
(1→2)-[α-L-rhamnopyranosyl-(1→3)]-β-D-glucopyranoside which also named as 
Longipenoside GL3 (Figures 31-33).
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Figure 31. 1H and 13C NMR of compound 8 (pyridine-d5, 800 MHz/200 MHz).
68
Figure 32. HMBC (H→C) of compound 8 (pyridine-d5, 800 MHz).
69
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Figure 33. HSQC (H→C) of compound 8 (pyridine-d5, 800 MHz).
3.1.9. Compound 9
Longipenoside GL4 (9) was identified as an amorphous powder with [a]
25
D -0.5 (c
0.2, MeOH). Its molecular formula was assigned as C54H90O21 through the negative
ion peak [M + HCOO]− at m/z 1119.6008 (calcd for C55H91O23, 1119.5957), and it 
had ten indices of hydrogen deficiency. Similar with the NMR of compound 8, 
those of 9 showed generally the same resonances. However, the difference of these 
compounds appeared at the additional rhamnose substituent at C-6'. According to 
NMR spectroscopic data, the presence of C-6' (δC 68.3, + 5.4 ppm) and HMBC 
correlation from H-1'''' anomeric proton (δH 5.43) to C-6' were strongly observed. 





Figure 34. 1H and 13C NMR of compound 9 (pyridine-d5, 500 MHz/125 MHz).
73
Figure 35. HMBC (H→C) of compound 9 (pyridine-d5, 500 MHz).
74
Figure 36. HSQC (H→C) of compound 9 (pyridine-d5, 500 MHz).
3.1.10. Compound 10
Triterpene 10 was obtained as a white amorphous powder with [a]
25
D -0.8 (c 0.2, 
MeOH). Its molecular formula was identified as C42H70O12 through an ion peak at 
m/z 811.4872 [M + HCOO]- (calcd for C43H71O14, 811.4849). The IR spectrum of 
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10 exhibited the absorption bands for several functionalities, including hydroxyl, 
carbonyl, and olefinic groups. The 1H NMR data revealed eight methyl groups (δH
1.66, 1.62, 1.42, 1.23, 1.17, 1.11, 0.89, 0.78), an oxygenated methine proton (δH
3.29), and an olefinic proton (δH 5.27). In addition, total 42 carbon signals were 
apparent in the 13C NMR spectrum, corresponding to a carbonyl carbon (δC 212.1), 
an oxymethine carbon (δC 88.7), and an oxygenated quaternary carbon (δC 73.6).
This result indicated that dammarane 10 contained one carbonyl group and two 
hydroxyl groups. The HMBC spectrum revealed the correlations from H-11 (δH
2.22), H-13 (δH 3.30), H-17 (δH 2.73) to C-12 (δC 212.1), from H-26 (δH 1.66), H-27 
(δH 1.62) to C-24 and C-25, indicating the presence of the carbonyl group and ∆
24,25
olefin system. The relative configuration of 1 was determined based on the NOESY
experiment. The α-orientations of H-3, H-5, and H-28 were established through the
correlations from H-3 (δH 3.29) to H-5 (δH 0.67) and H-28 (δH 1.23). To determine 
the sugar moieties, the NMR data revealed the presence of two anomeric protons, 
including a glucopyranosyl unit (d, J = 7.7 Hz) with the β-configuration and a 
rhamnopyranosyl unit (brs) with the α-configuration. In addition, the connection of 
these sugars was identified based on the HMBC correlations from H-1¢¢ (δH 6.56) 
and C-2¢ (δC 77.6).   Therefore, the structure of compound 10 was elucidated as 
3β,20(S)-dihydroxydammar-24-en-12-one-3-O-α-L-rhamnopyranosyl-(1→2)-β-D-
glucopyranoside which was also named as Longipenoside GL5 (Figures 37-41).
76
Figure 37. 1H and 13C NMR of compound 10 (pyridine-d5, 600 MHz/150 MHz).
77
Figure 38. HMBC (H→C) of compound 10 (pyridine-d5, 600 MHz).
78
Figure 39. HSQC (H→C) of compound 10 (pyridine-d5, 600 MHz).
79
Figure 40. COSY (H↔H) of compound 10 (pyridine-d5, 600 MHz).
80
Figure 41. NOESY (H↔H) of compound 10 (pyridine-d5, 600 MHz).
81
































































































































Figure 43. Key COSY and HMBC correlations of compounds 1, 2, 4, 7, 8, and 10.
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Figure 44. Key NOESY correlations of the dammarane skeletons of compounds 1, 
4, 8, and 10.
84
3.2. Insulin mimetic activity of triterpenoids from G. longipes
3.2.1. Cytotoxic effects of all isolated compounds on 3T3-L1 adipocytes and 
mouse C2C12 cells
Triterpenoids (1-10) (Figure 42) were measured cytotoxic effects in 3T3-L1 
adipocytes using the MTT method. Firstly, the cells were incubated with all 
compounds at 40 μM for 24 h, result in Figure 45A indicated compounds 1-9
showed no cytotoxic effects, but 10 dramatically reduced the percentage of cell 
viability. Then, compound 10 was performed another experiment at various 
concentrations (10, 20, and 30 μM). As shown in Figures 45B, compound 10
exhibited no toxicity only at 10 μM and its concentration was applied for the 2-
NBDG assay.   
In the C2C12 myoblast model, all isolated compounds were also evaluated the 
cytotoxic effects using the MTT method as described above. Similarly with the 
result in Figure 45, compounds 1-9 (40 μM) did not show any toxic to C2C12 
myoblast, except for compound 10 no cytotoxicity at 10 μM (Figure 46). 
85
Figure 45. The cytotoxicity effect of compounds 1-10 40 μM (A) and compound 
10 at different concentrations (B) in 3T3-L1 adipocytes. After 24 h of incubation
with test compounds, the MTT assay was carried out as described in the 
experimental section. Data are presented as the mean ± SD (n = 3), * p < 0.05, and 
*** p < 0.001, compared to the negative group.
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Figure 46. The cytotoxicity effect of all isolates 1-10 at 40 μM (A) and 10 at 
various concentrations (B) on C2C12 myoblasts. After the cells were treated with 
compounds for 1 day, the percentage of cell viability was evaluated using the MTT 
method. Result are presented as the mean ± SD (n = 3), * p < 0.05, ** p < 0.01, and 
*** p < 0.001, compared to the negative control.
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3.2.2. Stimulation effects of dammarane triterpenes from G. longipes on 2-NBDG 
uptake into the cells 
To measure glucose uptake into the cells, a fluorescent-tagged glucose analogue, 2-
[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG), was 
applied as a common method for in vitro study. In this research, triperpenoids 1–10
were evaluated for their stimulatory effects on glucose uptake using 3T3-L1 
adipocytes, which are more sensitive to insulin and more potential than other cell 
lines. Based on the fluorescence microscope method, the efficiency of 2-NBDG 
transport into cells was identified successfully by the fluorescent intensities in the 
adipocytes, comparison with that of the absence of 2-NBDG (Figure 47). In the 
presence of 2-NBDG, the fluorescent signals clearly induced when the cells were 
treated with compounds 1, 2, 4, 5, 8, and 10 (Figure 47, 48A). In addition, several 
compounds (1, 2, 4, and 8) were selected for further investigation the glucose 
uptake at different concentrations. Results in Figures 48B and 49 demonstrated 
these compounds significantly increased the 2-NBDG uptake into adipocytes in a 
dose-dependent manner.
88
Figure 47. Stimulation effect of isolates from G. longipes on 2-NBDG uptake in 
3T3-L1 adipocytes. The cells were exposed to insulin (100 nM) as a positive 
control, compounds 1-9 (20 μM), and 10 (10 μM). After incubation for 1 h, the
images of cells were then captured using a fluorescence microscope. The intensity 
of green fluorescence significantly induced, which suggested the successful 2-
NBDG transport into adipocytes.
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Figure 48. Enhancement of glucose uptake by compounds 1-10 in 3T3-L1 
adipocytes using a fluorescent analogue of glucose (2-NBDG). (A, B) The cells 
were treated with insulin (100 nM) and compounds at various concentrations in the 
presence or absence of 2-NBDG. After 1 h of incubation, the fluorescent intensity 
was evaluated at Ex/Em = 450/535 nm using a fluorescence microplate reader.
Each experiment was carried out in triplicate. Data are presented as the means ± 
SD (n = 3); * p < 0.05, ** p < 0.01, and *** p < 0.001, compared to vehicle. 
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Figure 49. Concentration-response relationships of the effects of several 
compounds on 2-NBDG in 3T3-L1 adipocytes. After incubation with compounds 1,
2, 4, and 8 (10 and 20 μM) or insulin (100 nM) in the presence of 2-NBDG for 1 h, 
the fluorescence and bright-field images were obtained using a fluorescence 
microscope.
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3.2.3. Evaluation of compounds 1, 2, 4, and 8 glucose uptake through GLUT4 
translocation
GLUT4 recently is a potential therapeutic target to treat T2DM. The regulation of 
GLUT4 translocation is necessary for the glucose absorption across the plasma 
membrane of adipocytes. According to previous studies, dammarane triterpenoids
(damulins A and B) from G. pentaphyllum have been reported as potential 
candidates for enhancing 2-deoxyglucose uptake and the translocation of GLUT4 
into the plasma membrane of skeletal L6 myotubes in a dose-dependent manner
(Nguyen et al., 2011). Therefore, in this study, compounds 1, 2, 4, and 8 were also 
evaluated stimulation effects on the GLUT4 translocation to the plasma membrane 
of 3T3-L1 adipocytes. Data in Figures 50 and 51 revealed the increasing of GLUT4 
translocation by these compounds as well as insulin (as a positive control). These 
results indicated that the effect of these compounds on glucose uptake was 
stimulated by the translocation of GLUT4 protein. Our data suggested that 
dammarane triterpenoids from G. longipes might be promising candidates for the 
development of antidiabetic drugs.
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Figure 50. Effect of strong candidates (1, 2, 4, and 8) on the translocation of 
GLUT4 to the plasma membrane of adipocytes. The cells were exposed to test 
compounds (20 μM) for 24 h or insulin (100 nM) for 2 h. The GLUT4 expression 
in the plasma membranes was measured using the Western blot method. Data are 
presented as the means ± SD (n = 3), * p < 0.05, compared to the negative group.
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Figure 51. Isolated compounds from G. longipes induced the translocation of 
GLUT4 to the plasma membrane of 3T3-L1 adipocytes; original uncropped blots. 
3T3-L1 adipocytes were exposed to compounds 1, 2, 4, and 8 (20 μM) for 24 h or 
insulin (100 nM) for 2 h. Then, the cells were collected at same time point and the
factions of plasma membrane fractions were isolated as described in experimental 
sections. The GLUT4 translocation was evaluated using Western blot analysis. 
Equal amounts of proteins were heated up to 37°C for 10 min and then loaded on 
SDS-polyacrylamide gels. After transferred to PVDF membranes, the blot was co-
incubated with GLUT4 and Na+/K+ ATPase α1 antibodies. (A) Sample names were 
from 1-6 as follows: Ctrl, insulin 100 nM, compounds 1, 2, 4, and 8 (20 μM). (B) 
Similarly, the membrane was also carried as above procedure. However, the blot 
was first detected the Na+/K+ ATPase α1 protein. Then, using a RestoreTM Western 
blot stripping buffer (Thermo Sci.) for removing bound primary and secondary 
antibodies, the band was continually incubated with GLUT4 antibody. Sample 
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names were from 1-7 as follows: Ctrl, insulin 100 nM, compounds 1, 2, 4, and 8
(20 μM), reload 8 (20 μM). (C) Collected cells (control and insulin groups) at 
different time points were also carried out. Sample names were from 1-10 as 
follows: Ctrl1 and Ctrl2 (collected after 24 h of experiment procedure), Ctrl3 and 
Ctrl4 (collected after 2 h of experiment procedure), insulin 100 nM-1 (treated at 22 
h point and collected after 24 h of experiment procedure), insulin 100 nM-2 
(collected after 2 h of experiment procedure), compounds 1, 2, 4, and 8 (20 μM) 
(collected after 24 h of experiment procedure). All bands were detected using 
LAS 4000 luminescent image analyzer. Figure A was included in final analysis 
(Figure 50).   
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3.2.4. Effects of dammarane triterpenes on AMPK signaling pathway
To investigate the underlying mechanism for the stimulation of 2-NBDG uptake 
into the cells by dammarane triterpenes from G. longipes, the effects of all 
compounds were evaluated on the AMPK pathway, which plays a key role in 
glucose uptake regulation. The effects of all isolated compounds on 
phosphorylation of AMPK were evaluated using mouse C2C12 myotubes. 
According to the Western blot evidence in Figures 52-55, it may be observed that 
compounds 1, 2, 4, 8, and 10 up-regulated significantly (p < 0.01) the expression of 
phosphorylated AMPK (p-AMPK). Weaker stimulation effects were observed in 
compounds 3 and 5 (p < 0.05). However, no significant activity was found for 
compounds 6, 7, and 9. Phosphorylated acetyl-CoA carboxylase (p-ACC) is a 
downstream signal of the AMPK signaling pathway that plays an important role in 
metabolic regulation. The function of AMPK is associated with fatty acid oxidation 
and regulation of the skeletal muscle metabolism via the phosphorylation of ACC1 
at Ser79. Thus, the level of p-ACC was measured by Western blot analysis with 
phosphorylated ACC antibody to better understand AMPK action in ACC 
phosphorylation. As shown in Figures 52-55, compounds 1, 2, 4, 8, and 10 also up-
regulated the expression of phosphorylated ACC. The results suggested that 
isolated compounds 1, 2, 4, 8, and 10 enhanced glucose uptake by regulating the 
AMPK signaling pathway. These results are consistent with the 
ethnopharmacological report of G. longipes as a traditional medicine for treating 
diabetes.
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Figure 52. Effect of isolated compounds 1-10 on p-AMPK (Thr172) and p-ACC 
(Ser79) in differentiated mouse C2C12 skeletal myoblasts. The cells were treated 
with compounds 1-9 (20 μM), and 10 (10 μM) or Aicar (0.2 mM) as an AMPK 
activator. After 1 h of incubation, the phosphorylation of AMPK and ACC proteins 
were evaluated using the Western blot method. The results were expressed as the 
means ± SD (n = 3), * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the 
negative control, p-ACC; # p < 0.05, ## p < 0.01, and ### p < 0.001, compared to the 
negative control of p-AMPK.   
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Figure 53. The effect of compounds 1-10 on p-AMPK Thr172 and p-ACC Ser79 in 
mouse C2C12 myotubes; original uncropped blots.
98
The cells were incubated with compounds 1-9 (20 μM), compound 10 (10 μM) or 
Aicar (0.2 mM) for 1 h. The cell lysates were then collected and the target proteins 
were measured using Western blotting method. Equal amounts of proteins were 
electrophoresed on 8% or 12% SDS-polyacrylamide gels and transferred to PVDF 
membranes. For detecting p-ACC Ser79 and ACC proteins, the 1X transfer buffer 
was added 0.5% SDS solution. Different membranes were cut based on protein 
sizes and incubated with primary antibodies for p-ACC Ser79, ACC. However, to 
measure the phosphorylation of AMPK protein, the blot was first detected p-
AMPKα Thr172 protein. Then, using a RestoreTM Western blot stripping buffer 
(Thermo Sci.) for removing bound primary and secondary antibodies, the blot was 
continually incubated with AMPKα and β-actin antibodies, respectively. All 
membranes were detected using a LAS4000 luminescent image analyzer. (A-D) 
Sample names were from 1-12 as follows: Ctrl, Aicar 0.2 mM, 1-9 (20 μM), 10 (10 
μM). Figure D was included in the final analysis (Figure 52).      
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Figure 54. The effect of compounds 1, 2, 4, and 8 at different concentrations (5 
and 10 μM) on the phosphorylation of AMPK (Thr172) and ACC (Ser79) in 
differentiated mouse C2C12 skeletal myoblasts. The results were calculated as the 
mean ± SD (n = 3), * p < 0.05, ** p < 0.01, and *** p < 0.001.
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Figure 55. Activation effects of compounds 1, 2, 4, and 8 from G. longipes on the 
phosphorylation of AMPK Thr172 and ACC Ser79 in C2C12 myotubes; original 
uncropped blots. 
The cells were exposed with tested compounds at different concentrations (5 and 
10 μM) or Aicar (0.2 mM) for 1 h. The phosphorylation of target proteins was 
evaluated using Western blot analysis. Equal amounts of proteins were loaded on 
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SDS-polyacrylamide gel. The gel was cut based on protein sizes and then 
transferred to PVDF membranes with different conditions (the 1X transfer buffer 
was added 0.5% SDS solution for detecting p-ACC Ser79 and ACC proteins). The 
blots were firstly detected with p-AMPKα Thr172 and p-ACC Ser79 proteins. Then, 
using a RestoreTM Western blot stripping buffer (Thermo Sci.), the membrane was 
further incubated β-actin antibody and detected by the LAS4000 luminescent 
image analyzer. Other gel was also cut and transferred as above described. The 
membranes were then incubated with AMPK and ACC antibodies and evaluated 
using a LAS4000 luminescent image analyzer. (A-B) Sample names were from 1-
13 as follows: Ctrl1, Ctrl2, Aicar (0.2 mM), 1 (5, 10 μM), 2 (5, 10 μM), 4 (5, 10 
μM), 8 (5, 10 μM), reload Aicar (0.2 mM), reload Ctrl1, respectively. (C) Similarly,
the cut-membranes were firstly detected the p-AMPKα Thr172 and p-ACC Ser79
proteins (blot 1). Then, these blots were further incubated with ACC, AMPK and 
β-actin antibodies. In addition, these samples were reloaded again on other SDS-
polyacrylamide gel. After transferred to PVDF membrane, the blot was detected 
the p-AMPKα Thr172 and β-actin proteins (blot 2). Sample names were from 1-13 
as follows: Ctrl1, Ctrl2, Aicar (0.2 mM), 1 (5, 10 μM), 2 (5, 10 μM), 4 (5, 10 μM), 
8 (5, 10 μM), reload Ctrl1, reload Ctrl2, respectively. Figure A was included in the 
final analysis (Figure 54). 
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4. Conclusions  
A 70% EtOH extract of G. longipes was subjected to various chromatographic 
columns and then to purification by preparative HPLC to afford ten new 
dammarane triterpenes (1-10) with two 3,4-seco dammarane analogues, 
secolongipegenins S1-S2 (1 and 2), a 3,4-seco hexanordammarane, 
secolongipegenin S3 (3), two hexanordammarane glycosides, longipenosides ND1-
ND2 (4 and 5) and five other dammarane glycosides, longipenosides GL1-GL5 
(6-10). There are included (1) 4,20(S)-dihydroxy-3,4-seco-dammar-24-en-12,23-
dion-3-oic acid, (2) 4,20(S),25-trihydroxy-3,4-seco-dammaran-12,23-dion-3-oic 
acid, (3) 4-hydroxy-3,4-seco-22,23,24,25,26,27-hexanordammaran-12,20-dion-3-
















Compounds 1, 2, 4, and 8 enhanced 2-NBDG uptake in a concentration dependent 
manner and stimulated the translocation of GLUT4 protein to the plasma 
membrane of 3T3-L1 adipocytes. 
It also observed that dammarane triterpenes (1, 2, 4, 8, and 10) significantly up-
regulated the expressions of phosphorylated AMPK and ACC using mouse C2C12 
myotubes. These results suggested that G. longipes may be a potential therapeutic 
agent for treating diabetes.
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Part 2. Neuroprotective Effects of Triterpenes from 





Neurological disorders are the leading cause of death and disability in the world
(Feigin et al., 2017). These disorders include Alzheimer disease, Parkinson's 
disease (PD), epilepsy, and cerebrovascular diseases,… Among them, PD is the 
second most common neurodegenerative disorder of the central nervous system 
(CNS) worldwide (Dawson and Dawson, 2003; Kwon et al., 2014; Lotharius and 
Brundin, 2002). Recently, PD is surpassing growth than Alzheimer disease (Dorsey 
and Bloem, 2018; Feigin et al., 2017). According to the Global Burden of Disease 
Study, the number of PD patients will increase to around 6.9 million in 2015 to 
14.2 million in 2040 (Dorsey and Bloem, 2018). 
PD is physiologically caused by dopamine deficits in the brain and the diminution 
of dopaminergic neurons in substantia nigra (Lin et al., 2012; Sashidhara et al., 
2014). PD patients present clinical symptoms such as rigidity, tremors, 
bradykinesia, and postural instability (Zhang et al., 2014). Diagnosing this disease 
has long been a challenge due to the complicated and progressive symptoms among 
different stages and the confusion with the symptoms of other CNS disorders
(Jackson-Lewis and Przedborski, 2007). The drugs used clinically for treating PD 
mainly include dopamine agonists and monoamine oxidase inhibitors (Meissner et 
al., 2011). However, these approaches only relieve the PD symptoms; they do not 
inhibit or reverse the neurodegeneration (Hsieh and Chiang, 2014).   
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1.2. Rotenone-induced Parkinson’s disease model
Nowadays, there are two types of PD including sporadic and familial PD. However, 
the most common form of this disease is sporadic PD which is caused by genetic 
susceptibility and environmental factors (Figure 56). Even though aging is an 
important risk factor for patients with sporadic PD, evidence has indicated that 
toxins exposure (such as rotenone, paraquat,…) is also associated with PD in 
humans (Exner et al., 2012; Wrangel et al., 2015). 
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Figure 56. The etiology of Parkinson's disease (Exner et al., 2012).
Rotenone, an inhibitor for mitochondrial complex I, is able to induce α-synuclein 
oligomerization and is able to produce intracellular reactive oxygen species (ROS)
(Figure 57) (Dadakhujaev et al., 2010; Luk et al., 2012; N. et al., 2017). Through 
this function, rotenone has been reported to be an effective reagent for mimicking 
the biochemical process of PD, and this model has been used to screen potential 
active compounds for PD treatment (Ryu et al., 2013). Considering the 
interrelationship between natural products and PD therapy, our group attempted to 
screen the Korea Bioactive Natural Material Bank (KBNMB) using a rotenone-
induced Parkinson’s disease model to search for new bioactive natural products 
with the potential for treating PD.
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Figure 57. Mechanism of rotenone induced apoptosis (N. et al., 2017).
1.3. Structure and aggregation of α-synuclein in PD
Human α-synuclein protein was encoded by the NG_011851 (SNCA) gene that 
consists of 6 exons (from 42 to 1110 bp). α-synuclein is a small acidic protein 
which contains 140 amino acid. It has been divided into three domains including a 
positively charged N-terminal region, a central hydrophobic region, and a highly 
acidic C-terminal domain (Emamzadeh, 2016; Rocha et al., 2018). Recently, the
functional role of α-synuclein is not fully understood, but several functions are
successfully identified and summarized in Table 5 (Emamzadeh, 2016). Especially,
soluble α-synuclein aggregates, known as oligomers, play an important role in the
development of PD through impairing many subcellular functions (Choi et al., 
2013; Colla et al., 2012). Substantial evidence indicates the phosphorylation of α-
synuclein at residue Serine-129 could enhance the aggregation of oligomeric α-
synuclein (Anderson et al., 2006; Rocha et al., 2018). Moreover, high levels of 
soluble oligomeric form induced cell death in both in vitro and in vivo models
(Rocha et al., 2018). Therefore, α-synuclein might be considered as a potential 
biomarker for PD.
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Table 5. The functions of α-synuclein (Emamzadeh, 2016).
α-synuclein function Target Mechanism
Suppression of apoptosis Protein kinase C Deactivation of nuclear factor κB (NFκB)
Regulation of glucose levels G-protein-couple-receptor
The pancreatic β-cell
KATP channel 
Increase tissue glucose uptake
Inhibition of insulin secretion
Modulation of calmodulin activity Calmodulin (CaM) Conversion of CaM from an inhibitor to an activator
Chaperone activity Presynaptic membranes Maintenance of sensitive factor attachment protein receptor
Maintenance of PUFA levels Acyl-coA synthetase Modulation of lipid synthesis
Antioxidation Cytochrome c oxidase 
c-Jun N-terminal kinase (JNK) interacting 
protein
Prevention of Caspases activation
Inhibition of JNK pathway
Neuronal differentiation Rab3a Activation of ERK/MAPK pathway
Regulation of dopamine biosynthesis Protein phosphatase 2A Inhibition of tyrosine hydroxylase
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1.4. The role of light chain 3 (LC3) in autophagy
Autophagy is a self-degradative process that may protect against neurological 
disorders such as PD. However, excessive autophagic activation could lead to 
depletion of essential proteins and it is responsible for programmed cell death
(Xiong et al., 2013). Currently, the overexpression of α-synuclein protein 
significantly activates the process of autophagy (Cuervo et al., 2004; Vogiatzi et al., 
2008; Xiong et al., 2009). Previous studies demonstrated that the early-stage of 
autophagy activation can response to protective effects and the late-stage of this 
process might result in cell death or neurotoxic effects (Xiong et al., 2013).
Light chain 3 (LC3), an autophagosomal marker protein in mammals, which is 
cleaved at its COOH terminus by the protease, resulting in the 
production of cytoplasmic LC3-I form. Conversion of LC3-I to LC3-II is tightly 
associated with the autophagosomal membrane probably through conjugation to 
phosphatidylethanolamine (Kabeya, 2004, 2000).
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Autophagy is initiated by the formation of the phagophore (known as isolation 
membrane). The complex process of autophagy pathway was shown in Figure 58. 
The major steps of this scheme are the interaction between p62 and LC3-II. The 
outer membrane of the autophagosome fuses with the lysosome and forms an 
autophagolysosome. The sequestered material is then degraded inside the 
autophagolysosome (vesicle breakdown and degradation) and recycled (Choi and 
Kim, 2013).




The plant C. japonica L., which belongs to the Theaceae family (Figure 59), is 
widely cultivated in Korea, China, and Japan (Nakamura et al., 2012; Tamaru et al., 
2013). In addition to its use as an ornamental or garden tree, C. japonica has 
important uses in traditional medicine. The flower buds of this plant has been used 
for treating vomiting of blood and bleeding, and showed anti-inflammatory, tonic, 
and stomatic activities (Nakamura et al., 2012). Previous phytochemical studies in 
our lab have found potential on protein tyrosine phosphatase 1B (PTP1B)
inhibitors (Uddin et al., 2014) and anti-PEDV (porcine epidemic diarrhea virus)
active compounds (Yang et al., 2015) from the fruit peels and flowers of this plant, 
respectively. Bioassay-guided fractionation using a rotenone-induced Parkinson’s 
disease model resulted in the isolation of six new 3,4-seco-28-nor-oleanane 
triterpenoids (11-16) from the flowers of C. japonica. In this report, we will 
describe the isolation and structural elucidation of the purified compounds 11-16, 
as well as their protective effects on SH-SY5Y neuronal cells in a rotenone model 
of Parkinson’s disease.
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Figure 59. Camellia japonica Linnaeus var. japonica: (1) flowering branch, (2) 
petals and stamens, (3) pistil, (4) young capsule. (5) Camellia japonica var. 
rusticana (Wu et al., 2007).  
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1.6. Purpose of research
The purpose of this study isolated new bioactive chemical entities using bio-guided 
strategy. During the process to screen the fractions from KBNMB using a 
rotenone-induced Parkinson’s disease model for treating PD, Camellia japonica
flowers could be protective effects on SH-SY5Y cells in rotenone-induced 
neurotoxicity. Triterpenoid, a major secondary metabolite of C. japonica, was 
chosen as target compounds. This thesis is organized as follows: (1) isolation of 
new seco-oleanane types based on the bio-guided assay, (2) study the effects of the
strongest candidate on the accumulation of α-synuclein and ROS levels and the 
condensation of chromosome a rotenone-induced Parkinson’s disease. The 
schematic representation of bio-guided isolation strategy is shown in Scheme 4.  
Scheme 4. The bio-guided isolation strategy of C. japonica flowers.
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2. Materials and methods
2.1. Plant materials
The flowers of Camellia japonica were collected from Gwangju city in February,
2013, and were authenticated by Prof. Oh Won Keun at Seoul National University.
A voucher specimen (SNU2013-02) was deposited at the College of Pharmacy, 
Seoul National University, Seoul, Republic of Korea.
2.2. Chemicals, reagents and chromatography
Almost chemical and bioassay reagents, and experimental instruments in Part 2 
were used similarly to Part 1. However, there have other chemicals and equipment 
in this part, including:  
- Random primer (iNtRON Biotechnology, INC, Korea)
- Maxima SYBR Green qPCR master mix 2X (Thermo sci., Rockford, IL, USA)
- α-synuclein antibody (SC-12767, Santa Cruz Biotechnology, INC.)
- DCFDA (D6883, Sigma-Aldrich, St. Louis, MO, USA)
- DAPI (Invitrogen, Eugene, OR, USA)
- Mounting medium (Vector, Burlingame, CA, USA)
- StepOnePlus Real-Time PCR System (Applied Biosystems)
- Carl Zeiss LSM710 confocal microscope (Carl Zeiss, Oberkochem, Germany).
2.3. Extraction and isolation schemes
C. japonica flowers (0.5 kg) were dried and extracted with 70% ethanol three times 
(each for 2 days) at room temperature. A concentrated crude residue (56 g) was 
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first suspended in deionized water (3 L, 40°C) and then successively partitioned 
against n-hexane, EtOAc, and n-BuOH. Screening in a rotenone model of 
Parkinson’s disease indicated that the n-BuOH fraction exhibited potential 
protective effects on SH-SY5Y neuronal cells, and this assay was used in the entire 
bioactivity-guided fractionation process (Scheme 5).
Scheme 5. Extraction and fractionation of C. japonica.
The n-BuOH fraction (11.2 g) was chromatographied over silica gel CC (5 ´ 40 cm) 
eluting with EtOAc/MeOH (from 20:1 to 1:1) to afford eight subfractions 
(CJF1-CJF8) according to the TLC profile. Fraction CJF3 (1.1 g) was further 
subjected to RP-C18 CC (1.0 ´ 20 cm) eluting with MeOH:H2O (1:1 to 1:0) to 
afford twenty subfractions (CJF3.1-CJF3.20). Fraction CJF3.8 (106 mg) was 
purified via HPLC [mobile phase: MeOH:H2O (85:15)], affording compound 13
(4.1 mg; tR = 24.3 min). Fraction CJF3.12 (190 mg) was separated by silica gel CC 
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(1.0 ´ 20 cm) eluting with n-hexane:EtOAc (3:1 to 1:1) to provide compound 15
(12.1 mg). Fraction CJ4 (1.6 g) was fractioned by Sephadex LH-20 CC (2.0 ´ 60 
cm) eluting with EtOH to afford six subfractions (CJF4.1-CJF4.6). Compounds 14
(6.3 mg; tR = 39.2 min) and 16 (13.2 mg; tR = 36.1 min) were purified from CJF4.3 
[301 mg; HPLC condition: mobile phase: MeOH:H2O (68:32)] and CJF4.4 [105 
mg; HPLC condition: mobile phase: MeOH:H2O (72:28)], respectively. Fraction 
CJF5 (2.0 g) was separated using a Sephadex LH-20 CC (2.0 ´ 60 cm) eluting with 
90% MeOH in H2O to yield ten subfractions (CJF5.1-CJF5.10). Fraction CJF5.6 
(325 mg) was purified using HPLC [mobile phase: MeOH:H2O (58:42)] to afford 
compound 12 (4.2 mg; tR = 40.6 min), and compound 11 (3.8 mg; tR = 27.6 min) 
was obtained from CJF5.7 (169 mg) via HPLC [mobile phase: MeOH:H2O (55:45)] 
(Scheme 6). 
Scheme 6. Isolation scheme of n-BuOH fraction of C. japonica.
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2.4. Chemical and spectral properties of isolated compounds
2.4.1. Compound 11
Compound 11 was obtained as a white amorphous powder; [a]25D -20.6 (c 0.1, 
MeOH); IR (KBr) νmax 3390, 2981, 1710, 1624, 1181, 910 cm
-1; 1H and 13C NMR 
data, Table 6; HRESIMS m/z 529.3140 [M + Na]+ (calcd for C29H46O7Na, 
529.3136).
2.4.2. Compound 12
Compound 12 was obtained as a white amorphous powder; [a]25D -24.1 (c 0.1, 
MeOH); IR (KBr) νmax 3394, 2920, 1715, 1631, 1032, 903 cm
-1; 1H and 13C NMR 
data, Table 6; HRESIMS m/z 1063.6682 [2M + Na]+ (calcd for C60H96O14Na, 
1063.6692).
2.4.3. Compound 13
Compound 13 was obtained as a white amorphous powder; [a]25D -26.4 (c 0.1, 
MeOH); IR (KBr) νmax 3420, 2958, 1714, 1642, 1008, 851 cm
-1; 1H and 13C NMR 




Compound 14 was obtained as a white amorphous powder; [a]25D -34.8 (c 0.1, 
MeOH); IR (KBr) νmax 3442, 2925, 1715, 1665, 1174, 829 cm
-1; 1H and 13C NMR 
data, Table 7; HRESIMS m/z 487.3423 [M − H2O + H]
+ (calcd for C30H47O5, 
487.3423) and 469.3317 [M − 2H2O + H]
+ (calcd for C30H45O4,469.3318).
2.4.5. Compound 15
Compound 15 was obtained as a white amorphous powder; [a]25D -27.2 (c 0.1, 
MeOH); IR (KBr) νmax 3394, 2958, 1730, 1614, 1385, 993 cm
-1; 1H and 13C NMR 
data, Table 7; HRESIMS m/z 529.3880 [M - H2O + H]
+ (calcd for C33H53O5, 
529.3893).
2.4.6. Compound 16
Compound 16 was obtained as a white amorphous powder; [a]25D -24.4 (c 0.1, 
MeOH); IR (KBr) νmax 3393, 2925, 1714, 1596, 1027, 951 cm
-1; 1H and 13C NMR 
data, Table 7; HRFABMS m/z 473.3283 [M + H]+ (calcd for C29H45O5, 473.3267).
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Table 6. NMR spectroscopic data for compounds 11-13.
11a 12b 13c
δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC
1 3.05, m 35.5, CH2 2.34, m 35.2, CH2 2.33, m 35.4, CH2
2.21, m 1.66, m 1.66, m
2 3.06, m 29.1, CH2 2.50, m 29.7, CH2 2.53, m 29.2, CH2
2.66, m 2.08, m 2.19, m
3 177.5, C 176.9, C 176.8, C
4 74.8, C 75.5, C 76.0, C
5 1.94, dd (10.0, 3.1) 50.5, CH 1.53, dd (11.3, 3.0) 50.9, CH 1.42, dd (10.8, 3.2) 52.9, C
6 2.05, m 34.5, CH2 1.52, overlap 33.8, CH2 1.45, overlap 33.5, CH2
1.99, m 1.30, overlap 1.29, overlap
7 4.19, dd (11.0, 4.5) 72.9, CH 3.74, dd (11.3, 4.1) 73.4, CH 3.59, dd (12.0, 4.8) 74.7, CH
8 46.0, C 46.2, C 40.9, C
9 2.07, br d (12.0) 39.6, CH 1.64, dd (10.0, 4.5) 40.0, CH 1.39, dd (11.2, 4.1) 39.5, CH
10 42.3, C 42.3, C 42.2, C
11 2.29, overlap 24.3, CH2 2.06, overlap 24.3, CH2 2.06, m 24.4, CH2
2.05. overlap 1.96, dt (16.2, 5.0) 1.96, dt (15.0, 5.0)
12 5.69, t (3.5) 125.4, CH 5.51, t (3.0) 126.2, CH 5.45, t (3.6) 126.1, CH
13 142.6, C 141.9, C 141.6, C
14 50.5, C 50.6, C 50.1, C
15 4.38, d (14.0) 47.6, CH2 3.52, d (14.0) 47.4, CH2 3.30, d (13.2) 43.4, CH2
3.06, d (14.0) 2.20, d (14.0) 1.66, d (13.2)
16 216.6, C 217.6, C 216.6, C
17 77.1, C 77.4, C 78.4, C
18 3.30, dd (14.5, 4.0) 53.2, CH 2.80, dd (14.3, 3.9) 52.1, CH 2.78, dd (14.4, 4.2) 53.1, CH
19 2.06, overlap 43.6, CH2 1.51, overlap 43.3, CH2 1.41, overlap 47.5, CH2
1.72, t (3.0) 1.33, overlap 1.38, overlap
20 37.1, C 36.9, C 31.8, C
21 2.23, dd (13.5, 4.5) 32.7, CH2 2.15, overlap 32.9, CH2 1.59, overlap 36.7, CH2
1.57, overlap 1.55, overlap 1.32, overlap
22 2.56, overlap 31.4, CH2 2.11, overlap 30.7, CH2 1.60, overlap 30.2, CH2
1.92, overlap 1.52, overlap 1.35, overlap
23 1.50, s 34.0, CH3 1.28, s 32.3, CH3 1.27, s 32.8, CH3
24 1.48, s 29.1, CH3 1.26, s 28.4, CH3 1.26, s 28.4, CH3
25 1.34, s 20.7, CH3 1.12, s 20.4, CH3 1.12, s 20.3, CH3
26 1.68, s 11.6, CH3 1.11, s 11.0, CH3 0.91, s 17.6, CH3
27 1.55, s 27.4, CH3 1.23, s 26.7, CH3 1.13, s 26.7, CH3
29 3.60, s 74.1, CH2 3.16, d (11.0) 74.2, CH2 0.90, s 30.2, CH3
3.13, d (11.0)
30 1.25, s 19.9, CH3 0.96, s 19.3, CH3 1.15, s 18.0, CH3
OMe 3.63, s 52.9, CH3
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OBu 1¢ 4.04, t (6.6) 65.4, CH2
OBu 2¢ 1.39, m 20.2, CH2
OBu 3¢ 1.59, m 31.8, CH2
OBu 4¢ 0.95, t (7.2) 14.1, CH3
a Recorded in piridine-d5 and at 500 MHz; 
b Recorded in methanol-d4 and at 500 MHz;
c Recorded in 
methanol-d4 and at 600 MHz.
Table 7. NMR spectroscopic data for compounds 14-16.
14a 15b 16a
δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC
1 2.46, m 35.2, CH2 2.33, m 35.4, CH2 2.10, m 34.8, CH2
1.52, m 1.65, m 1.57, m
2 2.58, m 29.8, CH2 2.54, m 30.2, CH2 2.40, m 30.6, CH2
2.17, m 2.18, m 2.09, m
3 175.2, C 176.7, C 174.9, C
4 75.4, C 76.0, C 148.3, C
5 1.41, dd (11.0, 3.0) 52.3, CH 1.39, overlap 53.1, CH 2.07, overlap 50.8, CH
6 1.55, m 23.1, CH2 1.50, m 23.2, CH2 1.69, m 25.3, CH2
1.49, m 1.47, m 1.38, m
7 1.60, m 33.2, CH2 1.61, m 32.9, CH2 1.55, m 32.4, CH2
1.52, m 1.39, m 1.26, m
8 40.5, C 40.9, C 40.3, C
9 1.81, dd (10.5, 6.5) 39.0, CH 1.78, dd (10.4, 6.0) 39.5, C 1.82, dd (10.8, 6.2) 37.9, CH
10 41.9, C 42.2, C 39.9, C
11 2.03, overlap 24.1, CH2 2.06, m 24.4, CH2 2.10, overlap 24.0, CH2
2.01, overlap 1.95, dt (15.8, 4.8) 1.94, dt (14.8, 4.2)
12 5.43, t (3.5) 124.9, CH 5.45, t (3.6) 125.7, CH 5.42, t (3.5) 124.4, CH
13 142.6, C 142.5, C 143.0, C
14 49.2, C 49.8, C 49.1, C
15 3.29, d (13.2) 43.2, CH2 3.33, d (13.2) 43.8, CH2 3.30, d (13.1) 43.3, CH2
1.62, d (13.2) 1.67, d (13.2) 1.63, d (13.1)
16 213.9, C 216.7, C 213.9, C
17 77.2, C 77.7, C 77.1, C
18 2.82, dd (14.0, 4.0) 52.6, CH 2.82, dd (14.4, 3.6) 52.6, CH 2.83, dd (14.0, 4.0) 52.6, CH
19 1.49, overlap 43.3, CH2 1.46, overlap 43.4, CH2 1.45, overlap 43.2, CH2
1.27, overlap 1.26, overlap 1.21, overlap
20 36.6, C 36.9, C 36.6, C
21 1.62, m 32.2, CH2 1.61, overlap 32.4, CH2 1.58, m 32.2, CH2
1.50, m 1.57, overlap 1.52, m
22 1.50, m 30.8, CH2 1.41, overlap 30.9, CH2 1.51, m 30.8, CH2
1.48, m 1.35, overlap 1.48, m
23 1.29, s 34.1, CH3 1.27, s 33.5, CH3 4.89, br s 114.0, CH2
4.74, br s
24 1.24, s 28.1, CH3 1.26, s 28.4, CH3 1.78, br s 24.4, CH3
25 1.15, s 20.3, CH3 1.13, s 20.4, CH3 0.98, s 19.8, CH3
26 1.14, s 17.9, CH3 1.15, s 18.0, CH3 1.18, s 17.9, CH3
27 1.16, s 26.8, CH3 1.17, s 26.9, CH3 1.19, s 27.1, CH3
29 3.16, br s 73.9, CH2 3.16, d (10.8) 74.2, CH2 3.17, d (10.0) 73.8, CH2
3.13, d (10.8) 3.14, d (10.0)
30 0.96, s 19.4, CH3 0.97, s 19.3, CH3 0.96, s 19.4, CH3
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OH-4 3.22, br s
OH-17 4.28, br s
OMe 3.57, s 51.4, CH3
OBu 1¢ 4.04, t (6.6) 65.4, CH2
OBu 2¢ 1.39, m 20.2, CH2
OBu 3¢ 1.59, m 31.8, CH2
OBu 4¢ 0.95, t (7.8) 14.1, CH3
a Recorded in acetone-d6 and at 500 MHz; 
b Recorded in methanol-d4 and at 600 MHz
2.5. Cytotoxicity assay
SH-SY5Y cells (human dopaminergic neuroblastoma cell line) were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) and Ham's F12 Nutrient Mixture 
(F12) (1:1, v:v) supplemented with 10% fetal bovine serum (FBS) (Gibco, NY, 
USA), 100 U/mL penicillin and 100 μg/mL streptomycin and incubated at 37°C 
under 5% CO2. The cytotoxicity assay was performed by staining with (3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) to measure cell 
viability. Briefly, Cells were seeded onto 48-well plates and grown to 70-80% 
confluence. Subsequently, the cells were pretreated with various concentrations of 
compounds 11-16 dissolved in low-serum medium supplemented with 5% FBS for 
24 h, and then 2.5 μM rotenone was added to the cells for 12 h. Then, 40 μL of a 2 
mg/mL MTT solution was added to each well and incubated for 4 h at 37°C in the 
dark. After discarding the medium, 250 μL of DMSO was added to each well to 
dissolve the MTT formazan crystals. The absorbance was measured at 550 nm 
using an absorbance microplate reader (VersaMaxTM, Randor, PA, USA). 
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2.6. Quantitative real-time PCR
Cells were seeded onto a 6-well plate and incubated for 1-2 days. When the cell 
confluence reached approximately 70-80%, the growth medium was replaced with 
low-serum medium in the presence of various concentrations of compound 15. 
After 24 h, the cells were treated with 2.5 μM rotenone and incubated for 12 h. 
Total RNA was isolated from the cells using the TRIzol method. The total RNA 
was reverse transcribed using random primer (iNtRON Biotechnology, INC, Korea) 
according to the manufacturer¢s instruction. Real-time PCR was performed using 
selective primers for α-synuclein (forward: 5'-AAG GAC CAG TTG GGC AAG 
AA-3', reverse: 5'-CCA CAG GCA TAT CTT CCA GAA TTC-3') and 18S 
ribosomal RNA (forward: 5'-GCT TAA TTT GAC TCA ACA CGG GA-3', reverse: 
5'-AGC TAT CAA TCT GTC AAT CCT GTC-3') and conducted using 2 µL of 
cDNA and Maxima SYBR Green qPCR master mix 2X (Thermo sci., Rockford, IL, 
USA). The cycling conditions for real-time PCR were as follows: 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Real-time PCR was 
conducted using a StepOnePlus Real-Time PCR System (Applied Biosystems). 
The data were analyzed using StepOne software v2.3.
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2.7. Western blot analysis
The cultures were prepared using methods similar to those for quantitative real-
time PCR. After 12 h, the cells were washed with cold PBS and stored at -80°C. 
For whole cell lysate, the cells were lysed on ice in 100 µL lysis buffer [50 mM 
Tris-HCl (pH 7.6), 120 mM NaCl, 1 mM EDTA, 0.5% NP-40, and 50 mM NaF] 
and centrifuged at 14,000 × g for 20 min. Supernatants were collected from the 
lysates, and protein concentrations were determined using a protein assay kit (Bio-
Rad Laboratories, Inc., CA, USA). Aliquots of lysates were boiled for 5 min and 
electrophoresed on 15% SDS-polyacrylamide gels. Protein in the gels were 
electronically transferred to nitrocellulose membranes (PVDF 0.45 µm, 
Immobilon-P, USA). The membranes were then incubated with primary antibodies 
α-synuclein (SC-12767, Santa Cruz Biotechnology, INC.) or mouse monoclonal 
actin antibody. The membranes were further incubated with secondary antibodies. 
Finally, they were detected using an enhanced chemiluminescence western blot 
detection kit (Thermo sci., Rockford, IL, USA) and quantified by 
LAS 4000 luminescent image analyzer (Fuji Film, Tokyo, Japan). 
2.8. Measurement of intracellular ROS levels 
The fluorescent probe 2¢,7¢- dichlorofluorescein diacetate (DCFDA), a well-known 
ROS indicator, was used to monitor intracellular ROS production in SH-SY5Y 
cells. Briefly, SH-SY5Y cells were seeded onto 96-well plates and grown to 70-80% 
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confluence. Then, the growth medium was replaced with low-serum medium 
supplemented with 5% of FBS in the presence or absence of various concentrations 
of compound 15. After 24 h of incubation, the cells were treated with 2.5 μM 
rotenone and incubated for 12 h at 37°C. The cells were then incubated with 20 μM 
of DCFH-DA (D6883, Sigma-Aldrich, St. Louis, MO, USA) for 30 min at 37°C in 
PBS supplemented with 0.5% FBS and then washed twice with PBS. The 
fluorescence intensity of the cells were monitored using a fluorescence microplate 
reader (Spectra Max GEMINI XPS, Molecular Devices, Sunnyvale, CA, USA) 
with excitation at 488 nm and emission at 530 nm. 
2.9. Confocal immunostaining 
HEK293 cells were grown in DMEM supplemented with 10% FBS (Gibco, Grand 
Island, NY, USA). A HEK293 stable cell line expressing GFP-LC3 was generated 
as described previously (LeBel et al., 1992) using a GFP-LC3 plasmid provided by 
T. Yoshimori (Yoon et al., 2012). For immunostaining, cells were grown on 
sterilized glass coverslips. After drug treatment, the cells were fixed with 4% 
paraformaldehyde. The slides were stained with 1 μg/mL 4′,6-diamidino-2-
phenylindole (DAPI) and mounted in mounting medium (Vector, Burlingame, CA, 
USA). Images were captured using a Carl Zeiss LSM710 confocal microscope 
(Carl Zeiss, Oberkochem, Germany). 
2.10. Statistical analysis
Statistical calculations were examined by analysis of variance (ANOVA), followed 
by Tukey’s range test, conducting in SPSS Statistics 20 (SPSS, Inc., Chicago, IL, 
USA). The results are presented as the means ± SD of two to three independent 
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experiments (* p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the rotenone 
treatment.
3. Results and discussion
3.1. Structural elucidation of isolated compounds (11-16)
3.1.1. Compound 11
Compound 11 was isolated as a white amorphous powder with [a]25D -20.6 (c 0.1, 
MeOH). Its molecular formula was assigned as C29H46O7, as determined from the 
HRESIMS peak at m/z 529.3140 [M + Na]+ (calcd 529.3136), which suggested 
seven degrees of unsaturation. The IR absorptions indicated the existence of 
hydroxy (3390 cm-1), carbonyl (1710 cm-1), and olefin (1624 cm-1) functionalities. 
The 1H and 13C NMR data (Table 6) showed one oxygenated methene (dH 3.60, 2H, 
s; dC 74.1 (CH2)), one oxymethine group (dH 4.19, 1H, dd, J = 11.0, 4.5 Hz; dC 72.9 
(CH)), two oxygenated quaternary carbons (dC 77.1 (C) and 74.8 (C)), one 
trisubstituted double bond (dH 5.69, 1H, t, J = 3.5 Hz; dC 142.6 (C) and 125.4 (CH)), 
one ketone group (dC 216.6 (C)), and one carboxylic carbon signal (dC 177.5 (C)). 
Moreover, there were 6 carbon signals in the 13C NMR spectrum assigned to 
methyl signals, which correspond to the 1H NMR peaks at dH 1.68, 1.55, 1.50, 1.48, 
1.34, and 1.25 (all s, each 3H) (Figure 60). The above results indicated that 
compound 11 was a 3,4-seco-28-nor-oleanane triterpene (Uddin et al., 2014). 
Compared with camelliaolean B (Uddin et al., 2014), there were no methoxyl 
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signals in the NMR spectra of compound 11 (Table 6), which indicated that a 
carboxylic group should be connected to C-2 in compound 11. This proposal was 
also confirmed by HMBC correlations from H2-1 (dH 3.05, 2.21) and H2-2 (dH 3.06, 
2.66) to C-3 (dC 177.5 (C)). In addition, the existence of one oxygenated methene 
group (dH 3.60, 2H, s; dC 74.1 (CH2)) in compound 11, together with the molecular 
formula, indicated the presence of one additional hydroxy group, which was 
bonded to C-29 (dC 74.1 (CH2)) on the basis of HMBC correlations from H2-29 (dH
3.60) and H3-30 (dH 1.25) to C-19 (dC 43.6), C-20 (dC 37.1), and C-21 (dC 32.7), as 
well as ROESY correlations from H-18 (dH 3.30) to H3-30 (dH 1.25). The 
assignments of the other functionalities were determined based on HMBC and 
ROESY experiments (Figures 61 and 62). The ROESY correlations from H-7 (dH
4.19) to H-5 (dH 1.94) and H-27 (dH 1.55), together with the coupling patterns of H-
5 (dd, J = 10.0, 3.1 Hz) and H-7 (dd, J = 11.0, 4.5 Hz), determined the a-
orientation of H-5 and b-orientation of OH-7. The chemical shifts of C-16, C-17, 
C-18, and C-22 (dC-16 215.3, dC-17 76.0, dC-18 52.2, and dC-22 30.3 in CDCl3), which 
were similar to those of camelliaolean B (dC-16 215.1, dC-17 76.3, dC-18 52.5, and dC-22
30.1 in CDCl3) (Uddin et al., 2014), were used to determine the b-orientation of 
OH-17. Finally, compound 11 was elucidated as 4,7b,17b,29-tetrahydroxy-16-oxo-
3,4-seco-28-nor-olean-12-en-3-oic acid.
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Figure 60. 1H and 13C NMR of compound 11 (Pyridine-d5, 500 MHz/125 MHz).
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Figure 61. HMBC of compound 11 (Pyridine-d5, 500 MHz).
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Compound 12, a white amorphous powder with [a]25D -24.1 (c 0.1, MeOH), was 
assigned a molecular formula of C30H48O7 based on a quasi-molecular ion at m/z
1063.6682 [2M + Na]+ (calcd 1063.6692) in the positive HRESIMS, which 
indicated seven degrees of unsaturation. The IR spectrum of 12 showed peaks that 
are characteristic of hydroxy (3394 cm-1), carbonyl (1715 cm-1), and olefin (1631 
cm-1) functionalities. With similar NMR patterns as found in compound 11, the 1H 
and 13C NMR data of compound 12 (Table 6) showed one oxygenated methene (dH
3.16 (1H, d, J = 11.0 Hz), 3.13 (1H, d, J = 11.0 Hz); dC 74.2 (CH2)), one 
oxymethine group (dH 3.74, 1H, dd, J = 11.3, 4.1 Hz; dC 73.4 (CH)), two 
oxygenated quaternary carbons (dC 77.4 (C) and 75.5 (C)), one trisubstituted 
double bond (dH 5.51, 1H, t, J = 3.0 Hz; dC 141.9 (C) and 126.2 (CH)), and one 
ketone carbon signal (dC 217.6 (C)) (Figure 63). An obvious difference was that 
compound 12 possessed one methoxyl group (dH 3.63 (3H, s); dC 52.9 (CH3)), 
which was connected to C-3 based on an HMBC correlation from the proton at dH
3.63 (3H, s) to C-3 (dC 176.9). Similar to compound 11, the a-orientation of H-5 
and b-orientation of OH-7 was determined from the coupling patterns of H-5 (dd, J
= 11.3, 3.0 Hz) and H-7 (dd, J = 11.3, 4.1 Hz) and from ROESY correlations from 
H-7 (dH 3.74) to H-5 (dH 1.53) and H-27 (dH 1.23). The ROESY correlations from 
H-18 (dH 2.80) to H3-30 (dH 0.96) supported the hydroxylation of Me-29. The 
chemical shifts of C-16, C-17, C-18, and C-22 (dC-16 215.5, dC-17 76.9, dC-18 51.9, 
and dC-22 30.2 in CDCl3), which were similar to those of camelliaolean B (dC-16
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215.1, dC-17 76.3, dC-18 52.5, and dC-22 30.1 in CDCl3) (Uddin et al., 2014), were 
used to determine the b-orientation of OH-17 (Figure 64). Therefore, compound 12
was determined to be 4,7b,17b,29-tetrahydroxy-16-oxo-3,4-seco-28-nor-olean-12-
en-3-oic acid methyl ester.
Figure 63. 1H and 13C NMR of compound 12 (methanol-d4, 500 MHz/125 MHz).
133
Figure 64. HMBC of compound 12 (methanol-d4, 500 MHz).
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3.1.3. Compound 13
Compound 13 was obtained as a white amorphous powder with [a]25D -26.4 (c 0.1, 
MeOH), and its molecular formula was determined to be C33H54O6 based on a 
positive HRESIMS ion at m/z 569.3819 [M + Na]+ (calcd 569.3813). The IR 
absorptions at 3420, 1714, and 1642 cm-1 were characteristic of hydroxy, carbonyl, 
and olefin functionalities, respectively. The 1H and 13C NMR data of compound 13
(Table 6) were very similar to those of compounds 11 and 12. The primary 
differences were the disappearance of the hydroxylation at Me-29 and the presence 
of an oxygenated n-butyl in compound 13 (dH 4.04 (2H, t, J = 6.6 Hz), 1.59 (2H, 
m), 1.39 (2H, m), 0.95 (3H, t, J = 7.2 Hz); dC 65.4 (CH2), 31.8 (CH2), 20.2 (CH2), 
and 14.1 (CH3)) (Figure 65). An HMBC experiment revealed that this oxygenated
n-butyl group was connected to C-3 based on the correlation of H2-1¢ (dH 4.04 (2H, 
t, J = 6.6 Hz) to C-3 (dC 176.8). Other functionalities were also determined as 
analyzed by HMBC correlations. Following the same procedure as for compounds
11 and 12, the orientation of both H-5 and H-7 was deduced from the coupling 
patterns of H-5 (dd, J = 10.8, 3.2 Hz) and H-7 (dd, J = 12.0, 4.8 Hz) and from 
ROESY correlations between H-7 (dH 3.59) to H-5 (dH 1.42) and H-27 (dH 1.13). 
The similarity of the chemical shifts of C-16, C-17, C-18, and C-22 in compound 
13 and camelliaolean B was used to determine the b-orientation of OH-17 (Figure 
66). Thus, compound 13 was identified as 4,7b,17b-trihydroxy-16-oxo-3,4-seco-
28-nor-olean-12-en-3-oic acid n-butyl ester.
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Figure 65. 1H and 13C NMR of compound 13 (methanol-d4, 600 MHz/150 MHz).
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Figure 66. HMBC of compound 13 (methanol-d4, 600 MHz).
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3.1.4. Compound 14
Compound 14, a white amorphous powder with [a] 25D -34.8 (c 0.1, MeOH), 
possessed a molecular formula of C30H48O6, as suggested by HRESIMS peaks at 
m/z 487.3423 [M – H2O + H]
+ (calcd 487.3423) and 469.3317 [M – 2H2O + H]
+
(calcd 469.3318). The IR spectrum of compound 14 presented absorptions that are 
characteristic of hydroxy (3442 cm-1), carbonyl (1715 cm-1), and olefin (1665 cm-1) 
functionalities. Its 1H and 13C NMR data (Table 7) showed an oxymethene (dH 3.16, 
brs; dC 73.9 (CH2)), two oxygenated quaternary carbons (dC 77.2, 75.4), one 
trisubstituted double bond signal (dH 5.43, t, J = 3.5 Hz; dC 142.6, 124.9), and two 
carbonyl carbons (dC 213.9, 175.2) (Figure 67). These observations indicated that 
compound 14 shared a similar structure with compound 12. The only difference 
was the disappearance of the oxymethine signals (dH 3.74, 1H, dd, J = 11.3, 4.1 Hz; 
dC 73.4 (CH)) in compound 12, suggesting the absence of OH-7 in compound 14. 
Other functionalities were determined based on HSQC and HMBC experiments. 
The relative configuration of compound 14 was determined through a ROESY 
experiment and comparison of NMR data with analogues. The ROESY correlations 
from H-18 (dH 2.82) to H3-30 (dH 0.96) indicated the attachment of one hydroxy 
group to C-29 (dC 73.9 (CH2)). The b-orientation of OH-17 was supported by the 
similarity of the chemical shifts of C-16, C-17, C-18, and C-22 (dC-16 215.0, dC-17
76.1, dC-18 52.3, and dC-22 30.2 in CDCl3) of compound 14 and those of 
camelliaolean B (dC-16 215.1, dC-17 76.3, dC-18 52.5, and dC-22 30.1 in CDCl3) (Uddin 
et al., 2014). The similar chemical shifts of C-4/5/6/10 in compound 14 (dC
75.4/52.3/23.1/41.9 in acetone-d6) and camelliaolean A (dC 75.4/52.4/23.2/41.8 in 
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acetone-d6) (Uddin et al., 2014) were used to determined H-5 as a-oriented, which 
was also supported by the coupling pattern of H-5 (dd, J = 11.0, 3.0 Hz) and the 
ROESY correlations from H-9 (dH 1.81) to H-5 (dH 1.41) and H3-27 (dH 1.16)
(Figures 62 and 68). Thus, compound 14 was determined to be 4,17b,29-
trihydroxy-16-oxo-3,4-seco-28-nor-olean-12-en-3-oic acid methyl ester.
Figure 67. 1H and 13C NMR of compound 14 (acetone-d6, 500 MHz/125 MHz).
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Figure 68. HMBC of compound 14 (acetone-d6, 500 MHz).
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3.1.5. Compound 15
Compound 15 was obtained as a white amorphous powder with [a]25D -27.2 (c 0.1, 
MeOH) and was assigned a molecular formula of C33H54O6 on the basis of a 
positive HRESIMS peak at m/z 529.3880 [M - H2O + H]
+ (calcd 529.3893). The 
IR peaks at 3394, 1730, and 1614 cm-1 suggested the presence of hydroxy, 
carbonyl, and olefin functionalities, respectively. Compound 15 shared a similar 
NMR pattern (Table 7) with compound 14. The characteristic difference is the 
replacement of the methoxyl group in 14 (dH 3.57, s; dC 51.4 (CH3)) by an 
oxygenated n-butyl group in 15 (dH 4.04, 2H, t, J = 6.6 Hz), 1.59 (2H, m), 1.39 (2H, 
m), 0.95 (3H, t, J = 7.8 Hz); dC 65.4 (CH2), 31.8 (CH2), 20.2 (CH2), and 14.1 
(CH3)), indicating n-butyl esterification of the carboxylic group at C-3 (Figure 69). 
This proposal was further supported by the HMBC correlation from H2-1¢ (dH 4.04) 
to C-3 (dC 176.7). Following the same procedure as compound 14, other 
functionalities and the relative configuration of 15 were determined via by HSQC
and HMBC experiments. The ROESY correlations from H-9 (dH 1.78) to H-5 (dH
1.39) and H3-27 (dH 1.17) and from H-18 (dH 2.82) to H3-30 (dH 0.97) indicated the 
a-orientation of H-5 and the hydroxylation at Me-29, respectively. The b-
orientation of OH-17 was supported by the similar chemical shifts of C-
16/17/18/22 (dC-16 215.2, dC-17 76.3, dC-18 52.3, and dC-22 30.1 in CDCl3) of 
compound 15 and those of camelliaolean B (dC-16 215.1, dC-17 76.3, dC-18 52.5, and 
dC-22 30.1 in CDCl3) (Figures 62 and 70) (Uddin et al., 2014). Finally, compound 
15 was elucidated as 4,17b,29-trihydroxy-16-oxo-3,4-seco-28-nor-olean-12-en-3-
oic acid n-butyl ester.
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Figure 69. 1H and 13C NMR of compound 15 (methanol-d4, 600 MHz/150 MHz).
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Figure 70. HMBC of compound 15 (methanol-d4, 600 MHz).
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3.1.6. Compound 16
Compound 16 was isolated as a white amorphous powder with [a]25D -24.4 (c 0.1, 
MeOH), and it had a molecular formula of C29H44O5 based on a positive 
HRFABMS peak at m/z 473.3283 [M + H]+ (calcd 473.3267). The IR absorptions 
indicated the presence of hydroxy (3393 cm-1), carbonyl (1714 cm-1), and olefin 
(1596 cm-1) functionalities. The 1H and 13C NMR spectra showed one oxymethene 
group (dH 3.17 (1H, d, J = 10.0 Hz), 3.14 (1H, d, J = 10.0 Hz); dC 73.8 (CH2)), one 
oxygenated quaternary carbon (dC 77.1), one trisubstituted olefin system (dH 5.42, 
1H, t, J = 3.5 Hz; dC 143.0, 124.4), one terminal double bond (dH 4.89 (br s), 4.74 
(br s); dC 148.3 (C), 114.0 (CH2)), and two carbonyl carbons (dC 213.9, 174.9). 
Further analysis indicated that the NMR patterns of compounds 11 and 16 were 
similar. However the CH-7 signals (dH 4.19, 1H, dd, J = 11.0, 4.5 Hz; dC 72.9) and 
the C-4 signal at dC 74.8 in compound 11 disappeared, whereas one terminal 
double bond (dH 4.89 (br s), 4.74 (br s); dC 148.3 (C), 114.0 (CH2)) was observed in 
compound 16, which suggested the absence of OH-7 and the presence of a D4,23
olefin system in 16 (Table 7 and Figure 71). This proposal was confirmed by 
HSQC and HMBC experiments, which also determined other functionalities in 
compound 16. The a-orientation of H-5, the hydroxylation of Me-29, and the 
relative configuration at C-17 was determined similar to those of compounds 11, 12, 
14, and 15, as analyzed by the ROESY correlation from H-9 (dH 1.82) to H-5 (dH
2.07) and H3-27 (dH 1.19), and from H-18 (dH 2.83) to H3-30 (dH 0.96) and 
comparing the chemical shifts of C-16/17/18/22 with those of compounds 11, 12, 
14, 15 and camelliaolean B (Figures 62 and 72). Therefore, compound 16 was 
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determined to be 17b,29-dihydroxy-16-oxo-3,4-seco-28-nor-olean-4(23),12-dien-
3-oic acid.
Figure 71. 1H and 13C NMR of compound 16 (acetone-d6, 500 MHz/125 MHz).
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Figure 72. HMBC of compound 16 (acetone-d6, 500 MHz).
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Figure 73. Six 3,4-seco-28-nor-oleanane triterpenoids (11-16) from C. japonica.
3.2. Neuroprotective effect of compounds 11−16 on rotenone-induced 
neurotoxicity of SH-SY5Y cells
A number of studies have demonstrated that a rotenone model of Parkinson’s 
disease has been established to search for candidates to treat PD (Ryu et al., 2013; 
Sala et al., 2013), in which human dopaminergic SH-SY5Y cells are exposed to 2.5 
μM of rotenone, a mitochondrial complex I inhibitor. The protection against 
neurotoxicity of compounds 1−6 was examined with this model. 
In the first step, the cytotoxicities of all isolated compounds 11−16 (Figure 73) 
were determined to estimate the optimum concentrations that are not toxic to SH-
SY5Y cells. Consequently, cytotoxicity was not observed when cells were treated 
with less than 20 μM of compounds 11, 12, and 14−16, except for compound 13, as 
shown in Figure 74A. Compound 13 was used at low concentrations of less than 10 
μM because of its cytotoxicity to evaluate protective action against rotenone-
induced dopaminergic cell death in SH-SY5Y cells. Therefore, 5-20 μM of 
compounds 11, 12, 14−16 and 1-5 μM of compound 13 were used to evaluate their 
neuroprotective effects on a rotenone model. As shown in Figure 74B, pretreatment 
of compounds 13−16 for 24 h increased cell viability against cell death resulting 
from treatment by 2.5 μM rotenone in a concentration-dependent manner. 
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Figure 74. Effects of compounds 11-16 on rotenone-induced cytotoxicity in SH-
SY5Y cells. (A) Effect of 3,4-seco-28-nor-oleanane triterpenoids 11-16 on the 
viability of SH-SY5Y cells. Each value expressed as the mean ± SD (n=2), * p < 
0.05, ** p < 0.01, and *** p < 0.001 compared to the vehicle. (B) Protective effect 
of compounds 11-16 on the neurotoxicity of SH-SY5Y cells in a rotenone model 
of Parkinson’s disease. Each value expressed as the mean ± SD (n=2), * p < 0.05, 
** p < 0.01, and *** p < 0.001 compared only to the rotenone treatment group.
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3.3. Effects of compounds 15 on α-synuclein expression induced by rotenone 
treatment
An abnormal accumulation of α-synuclein in the brain is a major feature of 
Parkinson’s disease (Dadakhujaev et al., 2010; Luk et al., 2012). Therefore, α-
synuclein could be a promising target for treating PD (Lee et al., 2014; Maries et 
al., 2003; T Rohn, 2012; Venda et al., 2010). In this study, we focused on the 
change of α-synuclein expression in the presence or absence of triterpenoids from 
C. japonica in SH-SY5Y cells using Western blot analysis and Real-time PCR 
method. Considering the cytotoxicities of compounds 11−16 and their protection
against neurotoxicity, compound 15 was selected for further evaluation on 
rotenone-induced neurotoxicity in SH-SY5Y cells. As shown in Figures 75 and 76, 
treatment with rotenone elevated the mRNA and protein expression level of α-
synuclein in SH-SY5Y cells, whereas pretreatment with compound 5 significantly





Figure 75. Relative mRNA and protein expression levels of α-synuclein against 
SH-SY5Y cells. 
The cells were pre-incubated with or without compound 15 at different 
concentrations for 24 h. Then, the cells were treated with 2.5 μM rotenone and 
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incubated for 12 h. (A) Compound 15 decreased the mRNA levels of a-synuclein 
induced by rotenone treatment in SH-SY5Y cells as assessed by real-time PCR.
Results were calculated as the mean ± SD (n = 3), * p < 0.05, ** p < 0.01, and *** 
p < 0.001 compared to the rotenone treatment group. (B) Compound 15 reduced 
the protein expressions of α-synuclein analyzed by Western blot. Data present as 
the mean ± SD (n = 2-4), * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to 
the rotenone treatment group.
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Figure 76. Effects of compound 13 and 15 on the protein expressions of α-
synuclein; original uncropped blots. 
The cells were pre-incubated with or without test compounds at various 
concentrations for 24 h. The cells were then exposed to 2.5 μM rotenone for 12 h. 
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Protein lysates were collected as described in experimental sections. Equal amounts 
of proteins were loaded on SDS-polyacrylamide gels. After transferred to PVDF 
membranes, they were blocked with 5% of skim milk solution. Then, different 
blots were incubated with α-synuclein or β-actin antibodies. All bands were 
detected using LAS 4000 luminescent image analyzer. Figure A was included in 
the final analysis (Figure 75).
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3.4. Effects of compound 15 on intracellular ROS production in a rotenone 
treatment model
Multiple studies have shown that over-expression of α-synuclein is potentially 
related with the increase of reactive oxygen species (ROS) by mitochondrial 
dysfunction, finally leading to neuronal cell death (Maries et al., 2003; Stefanis, 
2012). To examine the inhibitory action of ROS by compound 15, intracellular 
ROS generation was determined using a 2',7'-dichlorofluorescein diacetate (DCFH-
DA) assay in SH-SY5Y cells, as presented in Figure 77 (Gomes et al., 2005; LeBel 
et al., 1992). Treatment with rotenone significantly induced the ROS production 
compared with the non-treatment group. However, pretreatment with compound 15 
at various concentrations effectively decreased the ROS production induced by 
rotenone treatment in a concentration-dependent manner. 
Figure 77. Inhibition of intracellular ROS production by Compound 15. SH-SY5Y 
cells were pre-treated with or without compound 15 for 24 h. Rotenone (2.5 μM) 
was added to the cells and incubated for 12 h at 37°C. The cells were then 
incubated with 20 μM of DCFH-DA for 30 min. Values are expressed as the mean 
± SD (n = 3), * p < 0.05 and ** p < 0.01, and *** p < 0.001 compared only to the 
rotenone treatment group. 
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3.5. Compound 15 reduced the condensation of chromosome induced by rotenone 
treatment
Furthermore, we examined the autophagy regulation by rotenone and compound 15. 
Several studies have recently reported that autophagy is responsible for the 
clearance of α-synuclein induced by rotenone treatment. Considering that the 
autophagosomes which possess the LC3 in the membrane of vacuoles colocalized 
with α-synuclein-overexpressed aggregation as well as autophagic vacuoles were 
increased in rotenone-induced PD models (Xiong et al., 2013), autophagy induced 
by the treatment of compound 15 might contribute to the reduction of the α-
synuclein expression. The cells used in this study were stably transfected with 
GFP-LC3 vector, a commonly used autophagy marker (Kabeya, 2000; Yoon et al., 
2012), and sequentially treated with compound 15 and rotenone. While rotenone 
treatment caused chromosome condensation, compound 15 recovered rotenone-
induced chromosome condensation. Moreover, the formation of autophagosomes
was observed upon treatment with compound 15, suggesting that autophagy is 
modulated by the treatment with compound 15 (Figures 78 and 79). 
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Figure 78. Compound 15 reduced the condensation of chromosome induced by 
rotenone treatment in HEK293 cells stably expressing GFP-LC3 measured by the 
immunocytochemistry method.
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Figure 79. Compound 15 (20 μM) reduced the condensation of chromosome induced by rotenone treatment in HEK293 cells.
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4. Conclusions
Parkinson’s disease shows accumulation of abnormal aggregated protein (α-
synuclein) in neuronal cells, its clearance has been focused on as a treatment 
marker of this disease (Pan et al., 2009). Until present, there have been only two 
3,4-seco-28-nor-oleanane triterpenoids reported from Camellia without activity, 
and they were isolated from the fruit peel of C. japonica by our group in 2013
(Uddin et al., 2014). Herein, six new 3,4-seco-28-nor-oleanane triterpenoids 
(11−16) were isolated from the flowers of C. japonica, including (11) 4,7b,17b,29-
Tetrahydroxy-16-oxo-3,4-seco-28-nor-olean-12-en-3-oic acid, (12) 4,7b,17b,29-
Tetrahydroxy-16-oxo-3,4-seco-28-nor-olean-12-en-3-oic acid methyl ester, (13) 
4,7b,17b-Trihydroxy-16-oxo-3,4-seco-28-nor-olean-12-en-3-oic acid n-butyl ester, 
(14) 4,17b,29-Trihydroxy-16-oxo-3,4-seco-28-nor-olean-12-en-3-oic acid methyl 
ester, (15) 4,17b,29-Trihydroxy-16-oxo-3,4-seco-28-nor-olean-12-en-3-oic acid n-
butyl ester, (16) 17b,29-Dihydroxy-16-oxo-3,4-seco-28-nor-olean-4(23),12-dien-3-
oic acid.
Among isolated triterpenoids, compounds 13−16 exhibited potential protective 
effects on SH-SY5Y neuronal cells in a rotenone model of Parkinson’s disease.
Compound 15 significantly inhibited the accumulation of α-synuclein and ROS 
levels in the rotenone-treated SH-SY5Y cells. 
Compound 15 clearly reduced the condensation of chromosome which induced by 
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천연물은 새로운 당뇨치료제 개발에 있어서 유용한 자원이라 할 수
있으며 각지에서 과거로부터 민족의학적으로 유용하게 사용되어온 식물
중에서 과학적으로 기전과 효능이 평가되지 못한 식물이 많다.  
약용식물로부터 당뇨치료를 위한 소재를 발굴하는 연구를 진행하는 가운데, 
전통적으로 베트남에서 제 2형 당뇨병치료에 사용되어 왔던 Gynostemma 
longipes 잎의 95% EtOH 추출물이 2-NBDG를 사용한 assay에서 glucose 
uptake를유의적으로증가시키는것을확인하였다. G. longipes의생리활성과
화학성분에 대한 연구가 거의 되어 있지 않았기 때문에 본 연구는 항당뇨
생리활성을 나타내는 단일물질의 분리를 목적으로 수행되었다. Gynostemma 
longipes C.Y.Wu는 박과 (Cucurbitaceae) 에 속하는 다년생 덩굴성식물로서
베트남의 Ha Giang 지방의 허브농장에서 재배되어 수집되었다. 본 연구를
통하여 3,4-seco dammarane계열 3종 (1-3), hexanordammarane glycoside 계열
2종 (4-5), dammarane 계 glycoside 계열 5종 (6-10) 을 포함하여 총 10종의
신규물질을 분리하였으며 분리된 화합물의 구조는 UV, IR, NMR, MS/MS를
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포함한 이화학적 및 분광학적 분석과 기존문헌들과의 비교를 통하여
동정하였다. 분리된 화합물 10종에 대하여 분화된 3T3-L1 adipocyte에서 2-
NBDG를 사용한 glucose uptake에 미치는 활성을 평가하였을 때, 화합물 1, 2, 
4 및 8이 Glucose transporter type 4 (GLUT4) 전위 (translocation)을통하여강한
glucose uptake 촉진효과를 보였다. 세포 내로의 2-NBDG uptake 촉진효과의
기전을 확인하기 위하여 glucose uptake 조절에 중요한 역할을 한다고 알려진
AMPK pathway에 미치는 활성을 검색하였을 때, 화합물 1, 2, 4, 8 및 10이
mouse C2C12 근관세포 (myotube)에서 인산화된 AMPK와 ACC의 발현을
상향조절하는 것을 확인하였다. 위 결과들은 당뇨병 치료제로서의 G. 
longipes의전통적인용례와도일치함을알수있다. 
Part 2   
   Camellia japonica L. 은 차나무과 (Theaceae)에 속하는 상록수로서
한국, 중국, 일본에서 널리 자생하며 또한 재배되기도 한다. 전통적으로 C. 
japonica의 꽃봉오리는 상혈 (vomiting of blood), 출혈에 사용되었으며 강장, 
항염증의 목적으로도 사용되어왔다. 본 연구는 파킨슨병의 rotenone 
model에서신경보호효과를검색하는 assay를수행하였을때 C. japonica 꽃의
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70% EtOH 추출물이 강력한 신경보호효능을 나타내는 후보군으로
선정되었기에 본 활성을 나타내는 단일화합물 분리를 목적으로 실험을
수행하였으며 6종의 신규 3,4-seco-28-noroleanane 계열 triterpenoid (11-16) 를
분리하였다. 분리된 화합물의 구조는 UV, IR, NMR, MS/MS 를 포함한
이화학적 및 분광학적 분석과 기존문헌들과의 비교를 통하여 동정하였다. 
분리된 화합물에 대하여 신경보호활성을 평가하였을 때, 화합물 13-16 이
human dopaminergic SH-SY5Y 세포에서 효과적으로 신경독성에 대한
보호효과를 나타내었다. 특히 화합물 15의 경우, α-synuclein 발현과 rotenone 
처리에 의한 세포 내 활성산소발생을 억제함으로 강력한 세포보호활성을
나타내었다. 더욱이 이 화합물은 autophage marker 로 알려진 microtubule-
associated protein 1A/1B light chain 3 (LC3)을 유도하며 rotenone 처리에 의해
유도된 염색체 응축을 감소시켰다. 위 결과들을 종합하였을 때, 본 연구를
통하여 파킨슨 질병의 치료제개발에 있어 유용한 후보물질을 제시하였다고
사료된다.
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